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ABSTRACT 
 
Estrogen Therapy in a Viral Murine Model of Multiple Sclerosis. (August 2012)  
Francisco Pascual Gomez, B.S., Texas A&M University 
Co-Chairs of Advisory Committee: Dr. C. Jane R. Welsh 
          Dr. Jianrong Li 
 
 
Multiple sclerosis (MS) is an idiopathic neurodegenerative, demyelinating 
disease of the central nervous system (CNS). MS affects females more than males (3:1) 
and pregnancy reduces the number of relapses especially during the third trimester when 
17-β-estradiol (E2) and estriol (E3) are at their highest levels. In order to study the role of 
estrogens as potential therapeutic agents for MS we investigated their role in Theiler’s 
murine encephalomyelitis virus (TMEV)-induced demyelination (TVID).  
SJL female mice were infected intracranially with Theiler’s virus or PBS. The 
mice in the treatment groups were clinically scored and at week 20 they were 
ovarectomized (OVx) and given a subdermal pellet containing either 1) 0.1mg of E2, 2) 
5mg of E3, or 3) placebo. Four weeks after treatment initiation, the mice were sacrificed 
and  tissue samples were collected and vertebral columns and brains were fixed and 
placed in paraffin for histological analysis using either hematoxylin and eosin (H&E) 
stain for general anatomic features or Weil’s stain for myelin. 
No signs of clinical disease developed in any of the sham-infected mice. Prior to 
ovariectomy, infected mice had developed significant clinical scores indicative of 
demyelination. Mice in the placebo and E3-treatment groups deteriorated rapidly 
whereas the E2-treated mice improved significantly during the course of the treatment. 
Uteri were used to assess hormonal effects post-ovariectomy. Hormone treated groups 
were significantly different from placebo, indicating hormones were present. Hormone 
treatment showed significant differences among treatment groups for both inflammation 
and demyelination. E2-treatment significantly decreased inflammation compared to 
placebo and E3. E2 was also effective in reducing demyelination compared to placebo 
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groups but not E3. E3 treatment was effective in reducing inflammation compared to 
placebo, but no significance was found for demyelination. Both E3 and E2 treated mice 
developed lower antibody levels against TMEV. The improvement in clinical signs, 
inflammation, demyelination, and the reduction of antibody levels in 17-β-estradiol-
treated mice indicate a therapeutic potential for the treatment of MS.  
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NOMENCLATURE 
 
MS Multiple Sclerosis 
RRMS Relapsing-Remitting Multiple Sclerosis 
PPMS Primary Progressive Multiple Sclerosis 
SPMS Secondary Progressive Multiple Sclerosis 
CNS Central Nervous System 
BBB Blood-Brain Barrier 
TMEV Theiler’s Murine Encephalomyelitis Virus 
TVID Theiler’s Virus Induced Demyelination 
L-protein Leader Protein 
EAE Experimental Autoimmune Encephalomyelitis 
MBP Myelin Basic Protein 
PLP Proteolipid peptide 
MOG Myelin Oligodendrocyte Glycoprotein 
pfu Plaque forming units 
OVx Ovariectomy  
E2 17-β-estradiol 
E3 Estriol 
ER Estrogen Receptor 
H&E Hematoxylin and Eosin 
RIA Radio-Immuno Assay 
mRNA Messenger Ribonucleic Acid 
Ab Antibody 
ITAbP Intrathecal antibody production 
Ag Antigen 
MHC Major Histocompatibility Complex 
HLA Human Leukocyte Antigen 
ANOVA Analysis of Variance 
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DTH Delayed-Type Hypersensitivity 
CD Cluster of differentiation 
TH T-helper Cell 
TCL Cytolytic T-cell 
TReg Regulatory T-cell 
nTReg Natural Regulatory T-cell 
iTReg Induced  Regulatory T-cell 
IL Interleukin 
SCID Severe Combined Immunodeficient 
pg Picogram (1x10-12 grams) 
µg Microgram (1x10-6 grams) 
mL Milliliter (1x10-3 liters) 
NF-κB Nuclear Factor-kappa B 
PI3K Phosphatidylinositol 3-kinase 
TNF Tumor Necrosis Factor 
IFN Interferon 
MΦ Macrophage 
ASC Antibody-secreting Cell 
Ig Immunoglobulin 
TGF Transforming Growth Factor 
COX Cyclooxygenase 
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1.  INTRODUCTION 
  
 Multiple sclerosis, (MS) is a chronic inflammatory, demyelinating, and 
neurodegenerative disease of the central nervous system (CNS). It can lead to severe 
disability in young adults, and, according to Gasperini et al., it “is one of the most 
common causes of neurological disability in this population” (Gasperini et al., 2010).  It 
affects young adults between 15 and 45 years of age, thus making it a high-impact 
neurological disease because of its effect on the working age group (Owens et al., 2011). 
It is thought that in MS, different components of the immune system recognize and 
attack myelin. These include, autoreactive T and B-cells, cytokines, macrophages (MΦ), 
and antibodies (Ab) directed against myelin. The loss of myelin and axonal damage lead 
to the characteristic progression of symptoms (Gasperini et al., 2010). 
 Multiple sclerosis also has more impact on Caucasians and females with a reported 
female to male ratio of 2:1 and in some places 3:1, and it tends to affect people living in 
temperate climates (Gold and Voskuhl, 2009). In the United States alone, MS affects 
more than a quarter million people. MS affects the central nervous system, thus its 
effects severely affect the individual’s intellect as well as their ability to move and even 
their sight (Carlson, 2006). 
 
1.1 Etiology 
 The etiology of MS is thought to be caused by autoimmune damage to 
myelinated axons followed by degeneration of the axons. As described by Encarta  
 “[It] is chronic, unpredictable, and often progressive” and “[it] attacks and destroys 
tissues in the brain and spinal cord.”(Carlson, 2006).  There are four main types of MS. 
All forms affect nerve function, resulting in a variety of neurological manifestations. The 
most common type is the relapsing-remitting MS (RRMS). In this type, the patient has  
flare-ups and remissions –with periods where the patient does not show symptoms and 
___________ 
This thesis follows the style of the Journal of Neuroimmunology. 
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periods of pronounced disability. However, these patients do not deteriorate as fast as 
those with progressive MS. After a period of 10 years or more, 50% of MS patients may 
exhibit the Secondary-Progressive phase, which is like RRMS, but with increasing 
deterioration. Another type of MS that is not as common is Primary-Progressive MS 
(PPMS). In this form the patient just deteriorates steadily from the onset of the disease 
without any flare-ups and remissions. The rarest form of MS is the Progressive-
Relapsing form, which causes the worst symptoms in the shortest period of time. 
Although patients will have remissions, when the symptoms return they are more severe 
and the flare-ups experienced become increasingly worse (Carlson, 2006). 
 There are several schools of thought that address the possible etiology of MS. The 
most accepted theory is that in MS the immune system has a misdirected response 
against the myelin sheaths resulting in damage to the axons, which “leads to permanent 
loss of neurological function” (Gasperini et al., 2010). Myelin acts as an insulator to aid 
nerve impulses travel at velocities required to accurately relay information. When the 
immune system disrupts this myelin sheathing, the speed of transmission decreases or is 
completely interrupted. The neurological effects vary depending on the nerve affected. If 
the damage is in the pathway supplying the muscles it causes muscular problems, if on a 
sensory pathway, it may cause the loss of a sense, such as eyesight (Carlson, 2006).  
 A proposed mechanism for the immunopathogenesis of MS involves activation of 
autoreactive T-cells by an unknown factor. It has been proposed that molecular mimicry 
or bystander activation may be one of the factors leading to activation. Once activated, 
the T-cells can cross the blood-brain barrier (BBB) and possibly lead to its degradation. 
Once in the CNS, the cells can interact with Mφ, B-cells, or microglia and lead to the 
release of pro-inflammatory cytokines. Plasma cells can also migrate into the brain via a 
disrupted BBB and secrete antibodies against myelin proteins. This causes the 
degradation of the myelin sheath, recruitment of more inflammatory cells, and the 
release of free radicals, nitric oxide (NO), and proteases by local microglia. These events 
eventually culminate in tissue damage and axonal loss leading to the onset of symptoms 
(Gold and Wolinsky, 2011) 
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 Genetics also plays a role in the susceptibility to MS with an increase in the 
incidence in patients that have the HLA-DR2 genes of the major histocompatibility 
complex (MHC) Class II (Gold and Wolinsky, 2011). In addition, the interleukin 2 
receptor (IL-2RA/CD25) and interleukin 7 receptor (IL-7RA/CD127) genes have been 
identified as possible genetic components for MS (Gold and Wolinsky, 2011; Libbey 
and Fujinami, 2010; Olsson and Hillert, 2008). These findings give support to the 
autoimmune hypothesis, as MHC genes are involved in antigen presentation and certain 
alleles may predispose to reactions against self, or specifically against self-myelin. 
 Infectious agents, viruses or bacteria, have also been implicated in the 
pathogenesis of MS. Viruses implicated as  “suspect agents” that could trigger MS 
include: Epstein-Barr virus, Herpes simplex virus, Varicella zooster virus, 
Cytomegalovirus, Herpes hominis type-6 (Human Herpes Virus 6), measles virus, 
human T-cell lymphotrophic virus, or an endogenous retrovirus known as Human 
Endogenous Retrovirus (HERV) (Goodin, 2009; Libbey and Fujinami, 2010; Miller et 
al., 2001; Sato et al., 2011). Other evidence that favors a viral etiology include the 
following criteria according to Libbey and Fujinami (Libbey and Fujinami, 2010): 1) 
Characterization of MS lesions demonstrates CD8+ T-cells in infiltrates. The CD8+ T-
cells function in cell-mediated immunity to protect against viral infections; 2) Relapses 
in MS correlate with increases in viral titers during infection; 3) Antibodies against the 
various viruses mentioned previously have been detected in MS patients; 4) Peripheral 
infection can create molecular mimicry that can cause autoimmune reactions. When we 
consider all these possibilities and the fact that there has not been a clear association 
between the above viruses and MS patients, it becomes clear that isolating a single 
causal agent is improbable, especially in the case of mimicry (Libbey and Fujinami, 
2010).  
 Another mechanism, proposed to explain the pathogenesis of MS, hypothesizes 
that the disease arises as a result of viral infection combined with an overactive immune 
system which attacks myelin in genetically susceptible individuals. The infectious agent 
may also mimic host proteins, thus the immune system reacts and attacks both the 
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pathogen and host tissues (Carlson, 2006). This hypothesis may also explain the 
relapsing-remitting characteristic progression of the disease as well as other forms of 
disease progression. Epstein-Barr virus (EBV) infection has been implicated in other 
autoimmune disorders as well as in MS, including Sjorgen’s syndrome, rheumatoid 
arthritis, and systemic lupus erythematosus. In addition, some reports have found viral 
titers of EBV in MS brains and the diseases mentioned above (Goodin, 2009). Human 
Herpes Virus type 6 (HHV6) has also been found in MS lesions (Miller et al., 2001). 
However, there is an important point to be made in that many of the viruses isolated on 
MS brains have also been found in normal brains or have not been consistently detected 
in MS brains. Therefore, the etiology of MS may not be due to a single infectious agent 
but rather a variety of organisms. 
 A new hypothesis that was proposed by Stadelmann et al., suggests that the 
symptoms of MS may not only be due to demyelination. The neuro-axonal damage may 
also be due to a neurodegenerative component. This emerged as a result of evidence 
from cortical observations of different types of brain lesions in MS patients (Stadelmann 
et al., 2008). These cortical lesions, according to Calabrese et al., show less 
inflammation but do have demyelination, axonal loss and neuronal apoptosis, or cell 
death (Calabrese et al., 2008). Both studies agree that perhaps it is these cortical lesions 
that cause some of the more severe neurological manifestations of MS (Calabrese et al., 
2008; Stadelmann et al., 2008). The Stadelmann study, however, does recommend that 
these results be retested using more modern imaging techniques in order to obtain better 
data (Stadelmann et al., 2008). 
 
1.2 Main Basis for This Research Project 
Evidence for the autoimmune etiology of MS comes from its preference for the 
female sex. The most widely recognized autoimmune disorders that shows the strongest 
female prevalence is Sjörgen´s syndrome with a 95% incidence rate in females followed 
closely by systemic lupus erythematosus (SLE) at 90% incidence, and Multiple Sclerosis 
is in sixth place with an approximately 60% incidence rate (Whitacre, 2001). There is 
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also a marked difference in how these diseases present in males and females and there is 
also sexual dimorphism in the immune response. In a recent study by Smith-Bouvier et 
al., a novel model of mice was used to show if chromosomal gender had an impact in 
susceptibility to autoimmune disease. The group tested this hypothesis using XX and 
Sry-deficient XY- female mice and XXSry and XY-Sry male mice that were 
gonadectomized to examine the effects of chromosome complement without any sex 
hormones (Smith-Bouvier et al., 2008). They found that XX sex chromosome 
complement makes SJL mice more susceptible to both experimental autoimmune 
encephalomyelitis (EAE) and the pristane-induced lupus model (Smith-Bouvier et al., 
2008). In addition, the immune response is altered by XX complement, with XY- 
females producing anti-inflammatory TH2 cytokines such as IL-13 and IL-5 (Smith-
Bouvier et al., 2008). This may help explain why females may be more susceptible to 
autoimmune diseases, and why they are more often afflicted with MS.  
In animal models, females produce more antibodies and their T-cell activation is 
more robust. However, in human studies the only noticeable difference is that females 
have an increased absolute number of CD4+ lymphocytes but not necessarily increased 
levels of antibody or cytokines (Whitacre, 2001). Female hormones modulate the 
immune response and have been shown to dampen the TH1 response commonly seen in 
autoimmune disorders during pregnancy (Voskuhl, 2003; Whitacre, 2001). Males seem 
to have a higher prevalence of primary progressive Multiple Sclerosis (PPMS), 
especially when they are younger than 30 years of age with the male-to-female ratio of 
1:1 (Cottrell et al., 1999). As patients with this rare form of MS age, the ratio begins to 
switch to the traditional 1:2 seen in relapsing-remitting MS (RRMS) which may indicate 
a relationship with sex hormones: as female hormones decline with menopause the ratio 
seems to favor men whose testosterone levels remain into later decades of life (Cottrell 
et al., 1999). Testosterone has been shown to have a protective role by causing a shift 
toward a TH2 (antibody-mediated or humoral immunity) response that reduces the effect 
of autoimmune disorders, which are primarily TH1 (cell-mediated immunity) responses, 
and both testosterone and estrogens have been shown to have neuroprotective roles 
 6 
(Gold and Voskuhl, 2009). These observations prompted us to further investigate the 
relationship between sex hormones and the susceptibility of women to MS and the onset 
and severity of symptoms. 
The principal hormones that are addressed by this research project are the 
estrogens; namely, 17-β-estradiol (E2) and estriol (E3). These compounds are similar, 
with estriol having an extra hydroxyl (-OH) group. However, functionally these 
hormones perform totally different tasks. E3 is a hormone that increases to high levels 
during pregnancy. It is commonly referred to as a hormone of late pregnancy since it is 
produced by the fetal-placental unit (Sicotte et al., 2002). In contrast, E2 plays several 
roles in the body and it can be found in both males and females with females having 
much higher concentrations. In the Pregnancy in Multiple Sclerosis (PRIMS) European 
multicenter study, pregnant women with MS were recruited in between January 1993 
and July 1995. A total of 254 pregnant women responded to the study and the average 
relapses were obtained three months before pregnancy, during pregnancy, and three 
months after. Pregnancy has been shown to decrease the relapse rate especially during 
the third trimester, coinciding with the highest levels of estrogens and then increases 
markedly upon delivery as levels of estrogens fall (Abramsky, 1994; Confavreux et al., 
1998; Gold and Voskuhl, 2009; Rinta et al., 2010; Stuart and Bergstrom, 2011).  
Pregnancy seems to have an effect on the immune system shifting responses 
from TH1 to TH2 and in the case of diseases like MS, this setup could explain the marked 
decrease in the relapse rate (Confavreux et al., 1998). These observations have also been 
made when comparing pre-menopausal and post-menopausal patients noting that as 
endogenous estrogen levels wane in post-menopausal patients, the relapse rate increases 
(Smith and Studd, 1992). Clinical trials reported by Sicotte et al. and by Soldan et al. 
have shown estriol treatment in human patients as a promising treatment option for MS 
and suggests that hormones may indeed be playing a role in disease modulation in 
patients with MS (Sicotte et al., 2002; Soldan et al., 2003). In addition, hormonal 
therapy with oral contraceptives (OC) has shown a decrease in the number of relapses 
(Stuart and Bergstrom, 2011), the severity of symptoms, and the incidence of MS in OC 
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users was reported as 40% lower if the drugs used contained ethinyl estradiol and a 
progestagen when compared to non-users (Alonso et al., 2005; Nicot, 2009). 
Progesterone treatments in nonovariectomized experimental autoimmune 
encephalomyelitis (EAE) C57Bl/6 mouse models have shown that treatment with 100mg 
pellets give levels of progesterone comparable to pregnancy (~75ng/mL) and lead to an 
attenuation of symptoms and increased levels of protective cytokines, such as 
interleukin-10 (IL-10) (Garay et al., 2007; Yates et al., 2010). However, we will focus 
solely on the effects of estrogens as a means to observe hormonal effects on a viral 
model of MS.   
 
1.3 Theiler’s Murine Encephalomyelitis Virus (TMEV) Model 
 Researchers have used two murine – mouse – models in the majority of research 
related to MS, and each uses different approaches to establish the disease. The first 
model, which will not be addressed by this project, is the Experimental Autoimmune 
Encephalomyelitis (EAE) model. This model uses injections of myelin proteins with an 
adjuvant to cause an autoimmune attack on myelin. This is a purely non-infectious 
model that focuses exclusively on the autoimmune aspect of MS. To induce EAE, mice 
are inoculated with a myelin peptide, either Myelin Basic Protein (MBP) or proteolipid 
peptide (PLP), in complete Freund’s Adjuvant (CFA) containing Mycobacterium 
tuberculosis, and induced via injection with pertussis toxin (Bebo et al., 2001).  
 This project utilizes the Theiler’s murine encephalomyelitis virus (TMEV), which 
causes Theiler’s virus-induced demyelination (TVID) in susceptible mice strains. TMEV 
is a non-enveloped, positive sense, single stranded RNA virus belonging to the genus 
Cardiovirus, in the family Picornaviridae (Sato et al., 2011). TMEV has been divided 
into two subgroups: GDVII and Theiler’s original (TO). The Theiler’s original strains 
cause a persistent infection of the CNS in susceptible strains of mice, followed by 
demyelination whereas the GDVII strains cause lethal encephalitis is all strains of mice. 
This project will use SJL/J female mice since this strain is highly susceptible to 
developing a persistent demyelinating infection of the CNS.  
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The choice of model relates back to the proposed post-viral autoimmune etiology 
hypothesis. The TMEV model offers several similarities to human MS: First, it is a 
chronic inflammatory disease of the white matter with gray matter involvement; second, 
symptoms are caused by myelin breakdown, which is in turn mediated by a TH1 
response (mainly CD4+ cells); and third, mice develop autoimmune responses. In 
addition, disease can be spontaneously induced in mouse colonies because Theiler’s is a 
natural pathogen of mice (Miller et al., 2001). The most virulent groups of Theiler’s 
virus are the FA and GD-VII groups and they cause a fatal disease in mice known as 
acute polioencephalomyelitis (Oleszak et al., 2004; Roos, 2010). The onset of disease 
post-infection with either of the less virulent members of the Theiler’s Original (TO) 
group, the Daniels (DA) or the “tissue culture-adapted BeAn strain” is usually 
characterized by infection of the gray matter, especially motor neurons, leading to a 
poliomyelitis that may or may not be fatal (Miller et al., 2001; Sato et al., 2011). The 
mice that survive this period, develop a “chronic, progressive, inflammatory 
demyelinating disease” that persists primarily in the spinal cord (Miller et al., 2001; 
Roos, 2010). Like MS, the exact defined mechanism for demyelination induced by 
TMEV is unclear. Demyelination may arise as a result of either direct lysis of infected 
oligodendrocytes by the virus or by the immune system, or lysis of uninfected 
oligodendrocytes by an over-reactive immune system or via bystander responses (Libbey 
and Fujinami, 2010).  Comparable to progressive MS there is no clear gender bias with 
the Theiler’s virus model. However, in other strains such as the C57L/J, the opposite 
gender bias exists with males being severely affected and females showing more 
resistance (Fuller et al., 2005; Kappel et al., 1990). All these characteristics make the 
Theiler’s murine encephalomyelitis virus-induced demyelination (TMEV-ID) model, 
ideal to study the effect of hormones on MS. In this model, H&E stains characteristically 
show lymphocytic infiltrates in the parenchyma and around blood vessels (perivascular 
cuffing), meningitis, and status spongiosus. The lack of uptake of the Weil’s stain for 
myelin emphasizes areas of demyelination. The demyelinating lesions seen in TVID are 
very similar to those seen in human MS. In addition, there was a recent discovery of a 
 9 
cardiovirus related to TMEV that can infect humans, the Saffold virus (Chastain et al., 
2011; Roos, 2010). Thus the TMEV model may prove to be important to determine the 
mechanisms of MS pathogenesis. 
The main goal of this study was to determine the effectiveness of E2 and E3 as 
therapeutic agents for the treatment of (TMEV)-induced demyelination (TVID). We 
hypothesize that the immune modulatory properties of these two hormones will cause a 
decrease in clinical signs of disease and also decrease inflammation and consequently 
demyelination and neurodegeneration in the spinal cords of TMEV infected mice.  
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2. MATERIALS AND METHODS 
 
 
2.1 Project Design 
The project was divided into two main parts: Development of demyelinating 
disease as a result of infection and then hormone treatment. Figure 2.1 is a project 
timeline showing the events that took place from infection to termination. Table 2.1 
shows the project design and distribution of mice into groups. Originally eight (8) mice 
were assigned to each group. During the course of the experiment, two mice were lost in 
the TMEV-infected placebo treatment group. One mouse from each of the hormone 
treated uninfected groups died. 
 
 
 
 
Figure 2.1 Project timeline from infection to termination. 
 
 
 
Table 2.1 Project design.  
Group distributions for each treatment option 
 
17-β-estradiol (E2)  
(0.1 mg) treatment 
Estriol (E3) (5 mg) 
treatment 
Placebo treatment 
(Control) 
n=7 - Non-infected 
(PBS) 
n=7 - Non-infected 
(PBS) 
n=8 - Non-infected 
(PBS) 
n=8 - TMEV Infected n=8 - TMEV Infected n=6 - TMEV Infected 
 
 
 
Infection 
or PBS 
Ovariectomy+pellet: 
0.1mg E2 
5mg E3 
Placebo 
Termination 
20 weeks 24 weeks 5 weeks 
 11 
2.2 Subjects 
Groups of four female SJL mice (Jackson Labs) were assigned to twelve 
different cages (NTotal=48). The mice had access to food and water ad libitum. For this 
experiments six different experimental groups were created: three groups were infected 
with virus at 5 weeks of age and three groups were used as age-matched sham-infected 
controls. At 20 weeks of age (15 weeks post infection), all mice were ovariectomized 
(OVx) and then given either: a 0.1mg 17-β-estradiol (E2) pellet, a 5mg estriol (E3) pellet, 
or a placebo pellet placed subdermally (Bebo et al., 2001; Palaszynski et al., 2004; 
Wang et al., 2009). All animals were housed and handled in accordance with the Texas 
A&M University Institutional Animal Care and Use Committee (SACC) (AUP# 2007-
218, 2007-2010). 
 
2.3 Virus and Infection 
For this project, we utilized the BeAn strain of Theiler’s virus (obtained from Dr. 
H.L. Lipton, Department of Neurology, Northwestern University, Chicago, IL). The 
virus was previously propagated and amplified in BHK-21 cells and the culture 
supernatant was stored at -70ºC (Welsh et al., 1987).  
At 5 weeks of age, 24 mice (n=24) were anesthetized with isoflurane and 
infected intracranially into the right cerebral cortex with 5 x 104 plaque forming 
units/mL (pfu/mL) of the BeAn strain of TMEV. Controls (n=24) were given a similar 
injection with Phosphate Buffered Saline (PBS) intracranial injection into the right 
cerebral cortex 
 
2.4 Behavioral Measurements – Clinical Symptoms 
All mice were evaluated for clinical signs of disease weekly. This project focused 
on behavioral evaluations during the chronic phase of TMEV infection, paying close 
attention to trends in improvement after ovariectomy and treatment. We utilized a 
scoring system based on Borrow et al, 1998 and Sieve et al. (2004). The scoring system 
provides a range of values from 1 to 6. The scores were given as follows 
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1=some weakness in the hind limbs,  
2=slight wobble,  
3=wobbly gait,  
4=pronounced wobbly gait, loss of righting reflex, mice hunch or arch their 
backs,  
5=incontinence in addition to symptoms in 4, and  
6=moribund mice (Sieve et al., 2004).  
The data was obtained, averaged and plotted as a score vs time chart using Microsoft 
Excel.  
 
2.5 Tissue Samples and Preparation 
All mice were euthanized at 19 weeks p.i., which represents the 24th week of the 
experiment. The mice were perfused via the left ventricle with PBS followed by 10% 
formalin in phosphate buffer pH 7.2. The uteri, spleens, brains, and vertebral columns 
were collected. Uteri were weighed to assess exogenous hormonal effects on the mice 
and discarded after their weight was recorded. The spleens were flash frozen in liquid 
nitrogen and stored at -80ºC. The brains and spinal cords were dehydrated and embedded 
in paraffin blocks. They were stored at 4ºC until they were sectioned and stained 
(Campbell et al., 2001). 
The present study focused on lesions in the spinal cord since previous research 
has shown that the spinal cord is regularly affected during the chronic phase of the 
TMEV infection (Blakemore et al., 1988; Young et al., 2010). Vertebral columns 
containing intact spinal cord were removed and sectioned transversely into 12 pieces. 
Spinal cords were serial sectioned on a microtome at either 5µm for Hematoxylin and 
Eosin (H&E) staining or at 10µm for Weil’s staining. They were mounted on individual 
slides containing 12 sections per animal and covering cervical, thoracic, lumbar, and 
sacral/conus medullaris divisions of the spinal cord. 
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2.6 Light Microscopy and Image Captures 
 An Olympus VANOX AHBS3 microscope with an adapted digital camera was 
used for all image captures. Hematoxylin and Eosin (H&E) slides were captured at 40x 
magnification using a SPOT Insight QE digital camera (Diagnostic Instruments, Inc). 
Due to a software update and the purchase of a new camera, the Weil’s-stained slides 
were captured at 40x magnification using an SPOT RT Slider digital camera (Diagnostic 
Instruments, Inc). Both cameras had a 1.0x magnification. The software used for image 
capturing was SPOT Software version 4.6 (Imaging Solutions division of Diagnostic 
Instruments, Inc.) 
 
2.7 Hematoxylin and Eosin (H&E) Staining and Lesion Evaluation 
Sections of the paraffin-embedded vertebral column were cut at 5µm and then 
stained with H&E by Lin Bustamante at the Veterinary Integrative Biosciences (VIBS) 
Histotechnology Lab according to their established Hematoxylin and Eosin (H&E) 
staining protocol presented here: 
The sections were deparaffinized with three series of 15-20 dips each in Pro-Par 
Clearant and rehydrated in two 10-15 dips in 100% ethanol (EtOH). The sections 
were then dipped for two series of 10-15 times each in 95% EtOH and then in 
one series of 10-15 dips in 70% EtOH. The sections were washed three times 
with distilled water. The sections were stained in Hematoxylin 560 (Surgipath cat 
# 01571/Leica Microsystems cat # 3801571) for 4 minutes. Afterwards they were 
washed in tap water until clear. The slides then underwent a series of 2-3 quick 
dips in a solution made up of 1% hydrochloric acid (HCl) and 70% EtOH  (0.5% 
acid alcohol) to differentiate them. The sections were rinsed with tap water three 
times and were dipped 2-3 times in a 0.5% lithium carbonate (Li2CO3) solution 
(1.54g Li2CO3 in 100mL distilled H2O) to give them a blue tint. Once the 
sections are stained blue, they are washed in running tap water four times and 
rinsed with 10-15dips in 80% EtOH. The sections can then be counterstained in 
0.5% Alcoholic Eosin Y (StatLab, cat# SL98-1) in a series of 1-10 dips. The 
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sections are dehydrated using two series of 3-5 dips in 95% EtOH and three 
series of 10-20 dips in absolute EtOH. The stain was finalized by clearing using 
10-15 dips in xylene and then four series of 10-15 dips in Pro-Par Clearant. The 
slides were then mounted and cover-slipped.  
The TMEV model is characterized by inflammatory lesions of the spinal cord, 
and previous studies have shown restraint stress alters the immune systems response to 
TMEV in these areas using a categorical system of measurement based on lesion 
expression (Campbell et al., 2001; Sieve et al., 2006; Sieve et al., 2004). This project 
utilized area measurements to determine percent inflammation in the different spinal 
cord segments evaluated making the results more quantitative and facilitating 
interpretation (Campbell et al., 2001; Meagher et al., 2007; Sieve et al., 2004).  
Independent raters blind to the subjects’ treatment and condition were assigned 
different groups of mice and were asked to measure perivascular cuffing (perivascular 
accumulation of lymphocytes and macrophages) using ImageJ Software (National 
Institutes of Health). Status spongiosus (where possible demyelination could occur) were 
noted on the sections. All divisions of the spinal cord were measured on the slides – with 
the exception of the conus medullaris – at 40x magnification. 
The three measurements obtained from each section were: Total cord area, gray 
matter area, and area of inflammation (sum of areas, including cuffing and parenchymal) 
if applicable. White matter area was obtained using the equation: [Total cord area 
(pix2)]-[Gray matter area (pix2)]. Percent white matter inflammation was obtained by the 
equation: [Area of inflammation (pix2)]/[Total white matter area (pix2)]x100. The author 
supervised the raters and their data was checked for accuracy. Data was recorded on 
Microsoft Excel software. Analyses of the inflammatory lesions of the spinal cord were 
conducted for comparison of the percent parenchymal inflammation among groups.  
 
2.8 Weil’s Staining and Lesion Evaluation 
Demyelination was evaluated following staining of serial sections with the Weil's 
method for myelin. The Weil's stain uses iron alum and hematoxylin to visualize areas 
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with diminished myelin, or lipid-rich contents (Young et al., 2010). Sectioning (10µm) 
and staining were done by Lin Bustamante at the VIBS Histotechnology lab according to 
a modified protocol based on Arthur Weil’s original method (Weil, 1928): 
A stock solution of Weil’s solution is prepared by mixing 45mL of 4% ferric 
alum (FeNH4(SO4)2-12H2O) with 5mL of 1% stock hematoxylin solution. A 
solution of Weigert’s Borax ferricyanide solution is prepared by mixing 2g Borax 
(Sodium borate [Na2B4O7-10H2O]), 2.5g potassium ferricyanate (K3Fe(CN)6) in 
200mL of distilled H2O. A 0.5% solution of Lithium carbonate (Li2CO3) is 
prepared by mixing 0.5g Li2CO3 with 100mL distilled H2O.  
The sections were deparaffinized in absolute EtOH and placed in 0.5% celloidin 
for 10 minutes to prevent detachment from the slide, and were left to air dry for 
15 minutes. The slides were then placed in 70% EtOH for 5 minutes and then 
washed with distilled H2O. The slides were then placed in prepared Weil’s 
solution for 10-45 minutes at 50-60ºC. After that period of time, the slides are 
washed with tap water. Using the microscope, the slides are placed back in the 
Weil’s solution and checked for differentiation of white matter or areas of 
degeneration. Once the desired level is reached, the slides are washed with 
distilled H2O (several changes). To complete the differentiation, the slides are 
placed in the Weigert’s borax ferricyanide solution and checked under the 
microscope. Once the white matter/lesion areas are differentiated, the slides are 
again washed in several changed of distilled H2O, and then in tap water. The 
slides are placed in the Li2CO3 solution for one minute and then rinsed in 
sequence with tap and distilled H2O respectively. The slides are then dehydrated 
in EtOH, cleared in xylene and mounted and cover-slipped.  
Independent raters blind to the subjects’ treatment and condition used ImageJ Software 
(National Institutes of Health) to separately identify and outline areas of demyelination 
for each group assigned. All divisions of the spinal cord were measured on the slides – 
with the exception of the conus medullaris – at 40x magnification. 
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Once again, the three measurements obtained from each section were: Total cord 
area, gray matter area, and area of demyelination (sum of areas) if applicable. Each 
measurement was repeated twice and the values averaged. Average White matter area 
was obtained using the equation: [Average Total cord area (pix2)]-[Average Gray matter 
area (pix2)]. Percent white matter demyelination was obtained by the equation: [Average 
Area of demyelination (pix2)]/[Average Total white matter area (pix2)]x100. The average 
values were used for all analyses of the demyelinating lesions of the spinal cord. 
Statistical analyses were conducted for the percent parenchymal demyelination. Data 
was recorded on Microsoft Excel software. 
 
2.9 Theiler’s Virus Antibody (Ab) Levels 
Radio-Immuno Assays (RIAs) using Theiler’s virus (GD-VII) as antigen (Ag) were 
performed using the sera collected from each mouse at termination according to the 
protocol described by Sieve et al. (2004).  Flexible U-shaped, 96-well polyvinyl chloride 
plates (Costar, Cambridge, MA) were rinsed five times with Tween 20 (0.05%v/v) in 
Reverse Osmosis water (RO-H2O) and then rinsed five times with RO-H2O. The wells 
were then blot dried and 1µg/well of the Theiler’s virus antigen (GD-VII, 1.0x10-7 
pfu/100µL) in carbonate buffer (pH=9.6) was added to coat the bottom of the wells. To 
block the plate, 100µL of a buffer made of 495mL of a solution made from 0.08M 
Trizma HCl, 0.03M Trizma base, and 0.15M NaCl (final pH of 7.2), and 5mL of a 
solution made from 1.0% nonfat dry milk (NFDM) and 0.5% Tween-20 in RO-H2O. The 
plates were incubated for 24h at 4ºC. The plates were washed with Tween 20 (0.05%v/v) 
in Reverse Osmosis water (RO-H2O) and rinsed with RO-H2O once again and blocked 
with 3.0% NFDM in phosphate buffered saline (PBS, pH 9.0) using 200µL/well. The 
plates were incubated at 37ºC for 1h. After washing and blot drying, 10µL of mouse sera 
were added to the plates and diluted in 190µL of PBS containing 0.1% Bovine Serum 
Albumin (BSA) and NaN3 to create a 1/20 dilution. Serial dilutions were then made by 
taking 100µL of the 1/20 dilution, adding it to 100µL of PBS and mixing. The dilutions 
made were 1/40, 1/80, 1/160, 1/320, and 1/640. At the end, 100µL of the 1/640 dilution 
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were discarded to keep a 100µL volume per well. The plates were then incubated for 1h 
at 37ºC and washed as described above. Following the wash, 100µL of rabbit anti-mouse 
IgG diluted 1/500 from stock (Accurate Chemical and Scientific, New York) were added 
to each well. The incubation and washing was repeated, and then 100µL of Protein-A-
I125 (1x105 counts per minute [CPM]) were added to the wells and incubated at room 
temperature for 1h. After rinsing, the wells were cut and placed in tubes and radioactice 
counts read using a micromedic 4/200 plus automatic gamma counter (Sieve et al., 
2004).  
The results were transposed to Microsoft Excel and CPM to dilution charts were made 
for uninfected and infected mice and the respective treatment groups. 
 
2.10 Statistical Analysis 
The data is presented as Mean ± SEM. Data for behavioral/clinical scores was 
analyzed with Prism Software (GraphPad Software, Inc.) using the non-parametric 
Kruskal-Wallis test with Dunn’s Multiple comparison post hoc test. Data for uterine 
weights, spleen weights, and radio-immuno assays (RIAs) was analyzed with SPSS 
Statistics 20 (IBM) using a Two-way Analysis of Variance (2-way ANOVA) with a 
Least Squares Difference (LSD) post hoc test. Data for percent inflammation and percent 
demyelination, and comparison of the infected treatment groups in the RIAs was 
analyzed using a One-Way Analysis of Variance (1-way ANOVA) with a Least Squares 
Difference (LSD) post hoc test. For all data analyzed, statistical significance was 
achieved if p<0.05.  
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3. RESULTS 
 
3.1 Estradiol (E2)-treatment Ameliorates Clinical Signs of Disease 
Mice were evaluated once weekly for signs of disease and data is shown for 
scores beginning at week 17 post-infection (pi) in order to evaluate the chronic phase of 
TMEV infection. Scores for the weeks post treatment (Weeks 21-24) were averaged and 
evaluated for an effect of treatment on clinical symptoms of disease. Table 3.1 shows the 
mean weekly scores per treatment group and the overall mean score for the four-week 
treatment period. The overall mean clinical score for the placebo treated mice was 
3.8616 ±0.1057; whereas E2 treated mice scored 3.3750 ±0.0846 and for E3 treated 
mice 3.6719 ±0.0771. Figure 3.1 is a graphical representation of the mean scores. Non-
parametric Kruskal-Wallis analysis showed a significant difference among the all three 
groups for the mean weekly scores (H(2) : 6.865, p<0.05). The scores began to diverge 
and become significantly different among the three groups at weeks 23 (H(2) : 7.337, 
p<0.05) and 24 (H(2) : 10.39, p<0.05). The Dunn’s Multiple comparison post hoc test 
showed that E2 treatment significantly decreased clinical scores compared to placebo 
treatments at ameliorating scores post ovariectomy (p<0.05) but scores were not 
different from E3-treatment groups (p>0.05). There was no difference between placebo-
treated groups and E3-treated groups (p>0.05). Regression lines were fitted to each plot 
revealed that both placebo and E3-treated groups tend to increase in score severity as 
indicated by their positive slopes (m), while the E2-treated group seems to ameliorate 
based on its negative slope (m); however, the R2-value (R2=0.082) for the E2 regression 
line is not high enough to claim this effect. 
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Table 3.1 Mean weekly clinical scores. 
The mean clinical scores per experimental group are presented in this table in addition to the 
overall averages for the four-week treatment period 
 
 
Week Placebo Tx n=6 
E2 Tx 
n=8 
E3 Tx 
n=8 
Avg 21 3.7500 3.3125 3.5938 
SEM   0.0945 0.1619 0.2001 
Avg 22 3.6429 3.6250 3.5000 
SEM   0.1429 0.1250 0.1637 
Avg 23 3.9286 3.2500 3.7500 
SEM   0.1304 0.1336 0.2113 
Avg 
24 
(term.) 
4.1250 3.3125 3.8438 
SEM  
0.1548 0.1315 0.1151 
 
Overall 
Average 
3.8616 3.3750 3.6719 
 
SEM 0.1057 0.0846 0.0771 
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Figure 3.1 E2-treatment ameliorates the mean clinical scores when compared to placebo treatment.  
Scores following ovariectomy were significantly different among treatment groups (p<0.05). Hormone treatment with E2 began showing a 
marked effect compared to placebo. 
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3.1.1 Before-and-After Clinical Score Comparison Showed Both E2 and E3 Treatment 
Groups Exhibit Similar Rates of Disease Progression, but E2-treatment Maintained 
Lower Clinical Scores 
Table 3.2 shows the mean before and after scores per group comparing week 17, 
when we began measuring scores, to week 24 (termination). Figure 3.2 depicts this data 
graphically for the different treatment groups between week 17 and week 24 post-
infection. Regression lines fitted to the plots showed that all scores had a tendency to 
increase. Treatment with E2 had the same increase in score as E3 as indicated by the slope 
(m) of their respective regression lines (m=0.5938) and placebo-treatment showed the 
steepest increase in score (m=1.1875). Non-parametric Kruskal-Wallis analysis was used 
to compare the three groups at week 17 and week 24, respectively. No significant 
difference was found among groups during week 17 (H(2) : 3.572; p>0.05); however, the 
group scores were significantly different at termination (H(2) : 10.39; p<0.05). Though 
E2-treatment increased at the same rate as E3, the range of scores remained lower than 
E3. The final score of E2 treatment was significantly different from placebo (p<0.05) but 
not from E3-treated groups. There was no significant difference between E2 and E3 
treatment groups (p>0.05). 
 
 
 
Table 3.2 Mean clinical scores from week 17 and week 24. 
Mean clinical scores for both endpoints per group with the standard error are presented in this 
table. The average score per group is also shown 
 
Week Placebo n=6 
E2-Tx 
n=8 
E3-Tx 
n=8 
Avg 17 2.93750 2.71875 3.25000 
SEM   0.14752 0.26490 0.16366 
Avg 
24 
(term.) 
4.12500 3.31250 3.84375 
SEM   0.15478 0.13153 0.11512 
 
Average 3.53125 3.01563 3.54688 
 
SEM 0.59375 0.29688 0.29688 
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Figure 3.2 Mean clinical scores from weeks 17 and 24 show an increase in severity over the observation period. 
No significant difference was found among groups during week 17 (p>0.05). Group scores were significantly different at termination 
(week 24) (p<0.05). Though E2-treatment and E3-treatments both had the same slope, E2-treatment group scores remained lower than both 
E3 and Placebo-treated group scores. 
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3.2 Hormone Replacement Treatment Post-ovariectomy Causes Uteri to Increase in Size 
and Weight 
The mean uterine weights for both the uninfected and infected groups and 
hormone treatment subgroups are presented in Table 3.3. The uteri were collected and 
weighed after sacrificing the mice on week 24 of the experiment. The uteri were used to 
assess the effect of the hormones on the mice post-ovariectomy. Figure 3.3 presents the 
mean weight of the uteri graphically. A Two-way Analysis of Variance (ANOVA) was 
done to evaluate the difference between both uninfected and infected mice and their 
respective hormone treatment subgroups. There was a very significant difference in 
uterine weights among groups (F(5,43) : 68.098, p<0.05) that was influenced by hormone 
treatment (F(2,43) : 166.696, p<0.05) but not infection with virus (F(1,43) : 0.026, p>0.05). 
There was no interaction between virus and hormone (F(2,43) : 1.186, p>0.05). Further 
analysis, using Least Squares Difference (LSD) post hoc test showed no significant 
difference in uterine weights between E2 and E3-treated mice in either group (p>0.05), 
but a significant difference between these groups and placebo-treated mice (p<0.05) in 
both infected and uninfected mice.  
 
 
 
Table 3.3 Mean uterine weights in grams. 
Mean uterine weights for each group are presented along with the standard error. The top row 
represents uninfected groups and the bottom row represents infected groups 
 
E2+PBS 
n=7 
E3+PBS 
n=7 
Placebo+PBS 
n=8 
Avg 0.14614 0.14943 0.04288 
SEM 0.00896 0.00803 0.00505 
 
E2+Virus 
n=8 
E3+Virus 
n=8 
Placebo+Virus 
n=6 
Avg 0.15863 0.14250 0.03943 
SEM 0.00821 0.00389 0.00290 
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Figure 3.3 Graphical representation of the mean uterine weights obtained at termination. 
There was a significant difference among groups (p<0.05) with a main effect of hormone 
treatment (p<0.05). There was a significant difference between E2 and placebo (*) as well as 
between E3 and placebo groups in mean uterine weight (**) in both infected and uninfected 
groups. No significant difference (p>0.05) was found between E2 and E3-treated groups in either 
infected or uninfected groups. Data shown as Mean ± SEM. *p<0.05, **p<0.05 
 
 
 
3.3 Infection with Theiler’s Virus Has No Effect on Spleen Weights 
The spleens were collected and weighed after sacrificing the mice on week 24. 
Their weights were used to assess immune activation. Table 3.4 presents the mean 
weights and standard errors for the uninfected and infected groups and their hormone 
treatment subgroups, respectively. The three infected groups seemed to have smaller 
spleens than the uninfected groups, however, this did not reach significance. Figure 3.4 
presents the mean weight of the spleens graphically. A Two-way Analysis of Variance 
(ANOVA) was done to evaluate the difference between both uninfected and infected 
mice and their respective hormone treatment subgroups. There was no significant 
difference in spleen weights among groups (F(5,43) : 1.599, p>0.05). Infection with virus 
had an effect on spleen weights (F(1,43) : 7.912, p<0.05); however, hormone treatment 
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had no effect (F(2,43) : 0.004, p>0.05). There was no interaction between virus and 
hormone (F(2,43) : 0.012, p>0.05). 
 
 
 
Table 3.4 Mean splenic weights in grams. 
Mean splenic weights for each group are presented along with the standard error. The top row 
represents uninfected groups and the bottom row represents infected groups 
 
 E2+PBS 
n=7 
E3+PBS 
n=7 
Placebo+PBS 
n=8 
Avg 0.13271 0.13200 0.13175 
SEM 0.00984 0.00581 0.00467 
 
E2+Virus 
n=8 
E3+Virus 
n=8 
Placebo+Virus 
n=6 
Avg 0.11613 0.11463 0.11500 
SEM 0.00873 0.00729 0.00572 
 
 
 
 
Figure 3.4 Graphical representation of mean splenic weights obtained at termination. 
There was no significant difference among groups (p>0.05) despite having a main effect of 
infection with virus (p<0.05). Data shown as Mean ± SEM. 
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3.4 Treatment with E2 and E3 Diminishes the Percent Inflammation in the Spinal Cord 
Sections Compared to Placebo Treatment 
As previously mentioned, inflammatory lesions of the spinal cord characterize 
the Theiler’s Murine Encephalomyelitis Virus (TMEV) model. Area measurements were 
used to determine percent inflammation in the different spinal cord segments. We 
measured perivascular cuffing (accumulation of leukocytes around blood vessels) at 40x 
magnification. In addition, a note was made of areas with status spongiosus, which 
represent areas where demyelination may be inferred using H&E.  
The TMEV model’s inflammatory lesions are commonly found in cervical and 
thoracic spinal cord sections. Figure 3.5 A-D shows a representative sampling from each 
group using cervical spinal cord sections. The sections selected as representative for 
each treatment group had the mean scores of inflammation of that particular 
experimental group. All sections were taken at 40x magnification and were edited using 
SketchbookExpress (Autodesk) to remove excess structures (bone, muscle, etc). Panel A 
depicts an uninfected mouse, panel B depicts a placebo-treated infected mouse, panel C 
depicts an E2-treated infected mouse, and Panel D shows an E3-treated infected mouse. 
Within each panel, the red circles indicate perivascular cuffing and the red arrows 
represent status spongiosus, or the beginnings of demyelination. Similarly, Figure 3.6 A-
D shows a representative sampling in a similar manner but using thoracic spinal cord 
sections. 
Total cord area, gray matter area, and area of inflammation (sum of areas, 
including cuffing and parenchymal) were obtained using ImageJ (NIH). The white 
matter area was calculated and these data were used to obtain a percent white matter 
inflammation. The data was collected per mouse and later compiled leaving only white 
matter area and area of inflammation. These numbers were used to obtain a global 
percent inflammation per mouse and the averages and standard errors are presented in 
Table 3.5. This was the data used for statistical analysis. One-Way Analysis of Variance 
(ANOVA) with a Least Squares Difference (LSD) post hoc test was used to analyze the 
differences between groups. There was a significant difference among groups in 
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inflammation (F(2,21)  : 8.770, p<0.05). The LSD post hoc test revealed there was also 
significant difference between E2 and placebo (p<0.05), E3 and placebo (p<0.05), and 
between E2 and E3-treated groups (p<0.05) indicating an overall effect of treatment with 
E2 having the greatest effect. Figure 3.7 presents the compiled data graphically as Mean 
± SEM. 
 
 
 
Figure 3.5 H&E-stained cervical spinal cord sections from control and three different treatment 
groups.  
Panel A depicts a placebo-treated uninfected mouse. Panel B represents a placebo-treated 
infected mouse. Panel C represents an E2-treated infected mouse. Panel D represents an E3-
treated infected mouse. The red circles depict areas of perivascular infiltration and the red arrows 
represent areas of parenchymal inflammatory infiltration and status spongiosus. All images 
captured at 40x magnification 
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Figure 3.6 H&E-stained thoracic spinal cord sections from control and three different treatment 
groups.  
Panel A depicts a placebo-treated uninfected mouse. Panel B represents a placebo-treated 
infected mouse. Panel C represents an E2-treated infected mouse. Panel D represents an E3-
treated infected mouse. The red circles depict areas of perivascular infiltration and the red arrows 
represent areas of parenchymal inflammatory infiltration and status spongiosus. All images 
captured at 40x magnification 
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Table 3.5 Mean percent white matter inflammation. 
The mean percent inflammation and standard errors are presented for each treatment group 
  
Placebo Tx 
n=6 
E3 Tx 
n=8 
E2 Tx 
n=8 
Mean 0.76068 0.49727 0.25470 
SEM 0.10324 0.09385 0.05026 
 
 
 
 
Figure 3.7 Graphical representation for the mean white matter inflammation per treatment 
group. 
There is a significant difference among all three groups (p<0.05). Post hoc tests revealed a 
significant difference between E2 and E3-treated groups (*), E3 and placebo groups (**), and 
between E2 and placebo groups (***). Data presented as Mean ± SEM. *p<0.05, **p<0.05, 
***p<0.05 
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3.5 Treatment with E2 Reduces Demyelination in the Spinal Cord When Compared to 
Placebo  
The Weil's stain for myelin was used to detect demyelination. We identified and 
outlined areas of demyelination at 40x magnification.  
Similar to the location of inflammatory lesions, demyelinating lesions in TMEV 
are also found on primarily in cervical and thoracic spinal cord sections. Figure 3.8 A-D 
show a representative sampling from each group using cervical spinal cord sections. The 
sections selected as representative for each treatment group had the mean scores of 
demyelination of that particular experimental group. All sections were taken at 40x 
magnification and were edited using SketchbookExpress (Autodesk) to remove excess 
structures (bone, muscle, etc.). Panel A in Figure 3.8 depicts an uninfected mouse, panel 
B depicts a placebo-treated infected mouse, panel C depicts a E2-treated infected mouse, 
and Panel D shows an E3-treated infected mouse. Within each panel, the red arrows 
indicate areas of demyelination. Similarly, Figure 3.9 A-D shows a representative 
sampling using thoracic spinal cord sections. 
Once again, three measurements were obtained from each section: Total cord 
area, gray matter area, and area of demyelination (sum of areas) if applicable. The white 
matter area affected was obtained from calculations and used to obtain a percent white 
matter demyelination. The white matter area was calculated and these data were used to 
obtain a percent white matter demyelination. The data was collected per mouse and later 
compiled leaving only white matter area and area of demyelination. These numbers were 
used to obtain a global percent demyelination per mouse and the averages and standard 
errors are presented in Table 3.6. This was the data used for statistical analysis. One-
Way Analysis of Variance (ANOVA) with a Least Squares Difference (LSD) post hoc 
test was used to analyze the differences between groups. There was a significant 
difference among groups in inflammation (F(2,21) : 4.732, p<0.05). The LSD post hoc test 
revealed there was also significant difference between E2 and placebo (p<0.05). No 
significant difference was found between E3 and placebo (p>0.05), or between E2 and 
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E3-treated groups (p>0.05). Figure 3.10 presents the compiled data graphically as Mean 
± SEM. 
 
 
 
 
Figure 3.8 Weil’s-stained cervical spinal cord sections from control and three different 
treatment groups.  
Panel A depicts a placebo-treated uninfected mouse. Panel B represents a placebo-treated 
infected mouse. Panel C represents an E2-treated infected mouse. Panel D represents an E3-
treated infected mouse. The red arrows show areas of demyelination. Panel D is at the early 
stages of demyelination and the arrows point to primarily status spongiosus with the left arrow 
pointing at a small area of demyelination. All images captured at 40x magnification 
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Figure 3.9 Weil’s-stained thoracic spinal cord sections from control and three different 
treatment groups. 
Panel A depicts a placebo-treated uninfected mouse. Panel B represents a placebo-treated 
infected mouse. Panel C represents an E2-treated infected mouse. Panel D represents an E3-
treated infected mouse. The red arrows show areas of demyelination. Panel C shows no apparent 
signs of demyelination. All images captured at 40x magnification 
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Table 3.6 Mean percent white matter demyelination. 
The mean percent white matter demyelination and standard errors are presented for each 
treatment group 
 
Placebo Tx 
n=6 
E3 Tx 
n=8 
E2 Tx 
n=8 
Mean 13.35095 8.07803 4.54065 
SEM 2.02817 2.27615 1.47107 
 
 
 
 
Figure 3.10 Graphical representation of the mean percent white matter demyelination per 
group. 
There is a significant difference in percent white matter demyelination among all three groups 
(p<0.05). Post hoc tests revealed no significant difference between E2 and E3-treated groups 
(p>0.05), or E3 and placebo groups (p>0.05). However, there was a significant difference 
between E2 and placebo groups (*). Data presented as Mean ± SEM. *p<0.05 
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3.5.1 Serial Section Comparison between H&E and Weil’s-stained Spinal Cord Sections 
Allow Visual Co-localization of Inflammatory and Demyelinating Lesions 
H&E sections from representative mice were chosen as described previously and 
matched to the Weil’s stain serial sections to visually correlate inflammatory lesion 
location to demyelinating lesion location. All sections were captured at 40x 
magnification and were edited using SketchbookExpress (Autodesk) to remove excess 
structures (bone, muscle, etc.). Figure 3.11 A-D depict serial cervical sections. Row A 
represents cervical sections from control-uninfected mice from H&E and Weil’s stains, 
respectively. Row B represents sections from placebo-treated mice, row C represents E2-
treated infected mice, and row D represents E3-treated infected mice in the same manner 
as described above. Figure 3.12 A-D depict serial thoracic sections. Row A represents 
thoracic sections from control uninfected mice from the infection and demyelination 
studies, respectively. Row B represents sections from placebo-treated mice, row C 
represents E2-treated infected mice, and row D represents E3-treated infected mice in the 
same manner as described above.  
All the serial sections that show inflammation, also have signs of demyelination 
that can be co-localized to areas near perivascular cuffing and areas that show status 
spongiosus in H&E-stained sections. 
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Figure 3.11 Cervical spinal cord serial section comparisons between H&E (inflammation) and 
Weil’s (demyelination) stains.  
Row A represents control-uninfected mice, B represents placebo-treated infected mice, C 
represents E2-treated infected mice and D represents E3-treated infected mice. Bar = 150µm. 
40x magnification 
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Figure 3.12 Thoracic spinal cord serial sections between H&E (inflammation) and Weil’s 
(demyelination) stains.  
Row A represents control-uninfected mice, B represents placebo-treated infected mice, C 
represents E2-treated infected mice and D represents E3-treated infected mice. Bar = 150µm. 
40x magnification 
A 
B 
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3.6 Radio-immuno Assay Measurements of Theiler’s Virus Antibody (Ab) Levels Show 
Differences between Infected and Uninfected Groups and That Both E2 and E3-
Treatments Differ from Placebo in the Infected Groups 
Radio-Immuno  (RIAs) for Theiler’s virus antibody (GD-VII) were conducted on 
the sera collected from the mice at termination. The data was compiled and averaged by 
group to create Tables 3.7 and 3.8 and graphed as counts per minute (CPM) versus 
dilution as shown in Figure 3.13. Figure 3.14 shows the graphed CPM vs. dilution values 
for the infected groups only. By the 1/160 dilution, there are no detectable differences 
among control or infected groups. 
A Two-way Analysis of Variance (ANOVA) was done to evaluate the difference 
between both uninfected and infected mice and their respective hormone treatment 
subgroups at the 1/40 dilution, as this dilution is a good representative choice for the 
range of dilutions up to 1/160. There was a significant difference in Theiler’s Virus 
antibody (Ab) levels among groups (F(5,43) : 6.447, p<0.05). Infection with virus had a 
significant effect on Ab levels (F(1,43) : 15.124, p<0.05) as did hormone treatment (F(2,43) 
: 7.841, p<0.05). There was no interaction between virus and hormone (F(2,43) : 2.780, 
p>0.05) at the 1/40 dilution. Post hoc Least Squares Difference (LSD) analysis revealed 
that there was a significant difference between placebo and E3 (p<0.05) and between 
placebo and E2 (p<0.05) in the 1/40 dilution. No significant difference was found 
between E3 and E2 (p>0.05). 
A comparison of only the infected groups using 1-way ANOVA revealed similar 
significant differences among the three groups in the 1/40 dilution (F(2,21) : 5.579, 
p<0.05)). Post hoc Least Squares Difference (LSD) analysis revealed that there was a 
significant difference between placebo and E3 (p<0.05) and between placebo and E2 
(p<0.05) at the 1/40 dilution. No significant difference was found between E3 and E2 
(p>0.05).  
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Table 3.7 Average RIA counts per minute for treated, uninfected groups. 
The mean counts per minute for serial dilutions from 1/20 to 1/160 are presented in this table for 
each uninfected and treated mouse group. The 1/40 dilution was used for statistical analysis 
Control (n=8) 
Dilution 1/20 1/40 1/80 1/160 
Average 610.500 390.875 266.250 202.125 
SEM 200.219 114.143 63.818 59.379 
E3 Control (n=7) 
Dilution 1/20 1/40 1/80 1/160 
Average 307.857 194.857 147.429 115.143 
SEM 77.346 40.130 17.389 4.758 
E2 Control (n=7) 
Dilution 1/20 1/40 1/80 1/160 
Average 401.143 182.857 164.857 142.857 
SEM 178.105 15.251 14.287 13.869 
 
 
 
Table 3.8 Average RIA counts-per-minute for treated, infected groups. 
The mean counts per minute for serial dilutions from 1/20 to 1/160 are presented in this table for 
each infected and treated mouse group. The 1/40 dilution was used for statistical analysis 
Placebo Tx (n=6) 
Dilution 1/20 1/40 1/80 1/160 
Average 1,797.667 1,142.000 761.833 477.500 
SEM 446.942 328.822 210.086 112.335 
E3-Tx (n=8) 
Dilution 1/20 1/40 1/80 1/160 
Average 475.500 315.500 262.875 222.875 
SEM 86.689 45.293 33.625 16.576 
E2-Tx (n=8) 
Dilution 1/20 1/40 1/80 1/160 
Average 976.250 577.375 399.750 299.250 
SEM 217.872 112.100 67.546 60.535 
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Figure 3.13 Radio-immuno assay analysis for TMEV antibody levels in the sera of uninfected and infected mice.  
Data for the 1/40 dilution was chosen as a representative sample for the assay. Dashed lines represent control-uninfected groups and the 
solid lines represent treated-infected groups. There was a significant difference among groups in Ab levels to TMEV (p<0.05) with a main 
effect of virus infection (p<0.05) and hormone treatment (p<0.05). There was no interaction between virus and hormone (p>0.05). There 
was a significant difference between E2 and placebo (*) as well as between E3 and placebo groups for TMEV Ab levels (**) in both 
infected and uninfected groups. No significant difference (p>0.05) was found between E2 and E3-treated groups in either infected or 
uninfected groups. Data shown as Mean ± SEM. *p<0.05, **p<0.05 
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Figure 3.14 Radio-immuno assay analysis for TMEV antibody levels in the sera of infected mice 
This graph presents the data for the 1/40 dilution of TMEV infected groups only. There is a significant difference (p<0.05) among all three 
groups in Ab levels. No significant difference was found between E3 and E2 (p>0.05). Placebo treated mice differ significantly from both 
E2-treated (*) and E3-treated mice (**). Data is presented as Mean±SEM. *p<0.05, **p<0.05 
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4. DISCUSSION 
 
This project assessed the effect of hormone-replacement therapy on the chronic 
phase of Theiler’s Murine Encephalomyelitis Virus (TMEV) infection. The data analysis 
focused on observations from week 15 post-infection (pi), which corresponds to week 17 
of the experiment. Chronic demyelination in the Theiler’s infection model is considered 
to begin 2-5 months pi and remain for the life of the mouse causing progressive disease 
similar to progressive human multiple sclerosis (Miller et al., 1995). For our treatments, 
we chose a 0.1mg pellet based on previous experiments performed by Bebo et al., which 
indicated this dose, equivalent to diestrus levels of 17-β-estradiol (E2) in mice (25-
50pg/mL) was effective in significantly reducing EAE clinical scores compared to 
placebo (Bebo et al., 2001). Because estriol (E3) is a hormone of pregnancy produced by 
the fetal-placental unit (Sicotte et al., 2002), we used information from Bebo et al. and 
from Palaszynski et al. to select a 5.0mg E3 pellet, which would give pregnancy 
hormone level equivalents (2000-3000pg/mL), this level of E3 in circulating blood 
reduced incidence of EAE compared to placebo (Bebo et al., 2001; Palaszynski et al., 
2004). The levels of E2 and E3 chosen led to increases in uterine size. For both infected 
and uninfected groups, the weight of the uteri was significantly different than placebo-
treated mice. Because the mice were ovariectomized, this measurement allowed us to 
determine the effectiveness of the hormone replacement. Our results indicate that the 
doses of E2 and of E3 we selected have a positive effect on inflammation. The spleen is 
an important secondary lymphoid organ, our results showed that the spleens in the 
infected groups on average weighed less than those of the uninfected groups; however, 
our results showed no significance in weight. This is consistent with findings by 
Mendez-Fernandez et al., who showed the spleen was not necessary for TMEV-specific 
CD8+ cell-activation and recruitment (Mendez-Fernandez et al., 2005).  
The current study showed that E2 has therapeutic effects on the Theiler’s Virus-
Induced Demyelination (TVID) model of multiple sclerosis. Our experiments 
demonstrated that treating young ovariectomized female mice with estradiol reduced 
clinical signs of disease as well as histological signs of inflammation and demyelination 
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in the spinal cord. These findings were consistent with our hypothesis. Treatment with 
E3 also was effective in reducing signs of inflammation; however, it showed no 
difference from placebo-treated mice in improvement of clinical scores or 
demyelination. In the experimental autoimmune encephalitis (EAE) model, females that 
were ovariectomized but not treated did not show altered disease severity when 
compared to placebo-treated non-ovariectomized mice. This indicates that physiological 
levels of estrogens may not be enough to cause any effect on disease progression in this 
model once the disease has begun (Voskuhl and Palaszynski, 2001). Conflicting results 
were shown if treatment with physiologic levels of E2 and E3 were administer prior to the 
onset of EAE (Bebo et al., 2001). Ovariectomy may have been a factor for the lessened 
effect of E3 in our experiment; however, EAE model is a pure autoimmune model that 
does not account for the effects of the virus present in TVID; rather it directs a CD4+ 
response to myelin components (Miller et al., 1995). Nevertheless, E3 has been shown to 
be protective in studies with human MS patients and in the non-ovariectomized EAE 
model of MS (Palaszynski et al., 2004; Sicotte et al., 2002; Spence and Voskuhl, 2012). 
It is difficult to assess the reason behind the inability of E3 treatment to diminish 
demyelination. Perhaps the length of treatment was not sufficient to allow the hormone 
to have an effect. 
The discrepancy in our results could be explained by differences in the binding of 
estriol versus estradiol to estrogen receptors (ERs). Both estriol and estradiol can bind to 
estrogen receptors α and β (ERα and ERβ, respectively). However, estradiol has a higher 
affinity for ERα while estriol has a higher affinity for ERβ (Spence and Voskuhl, 2012). 
ERα has been implicated in EAE as having a potent anti-inflammatory response. 
Binding of E2 to ERα inhibits the transport of the pro-inflammatory transcription factor 
NF-κB into the nucleus via interaction with PI3K, most notably in microglia, the resident 
macrophages of the CNS (Spence et al., 2011; Vegeto et al., 2008). In ischemia, ERα-
mediated suppression of these cells and other inflammatory cells seems to be responsible 
for neuroprotection in young female rats post-stroke (Selvamani and Sohrabji, 2010). In 
vitro experiments have shown that stimulation of ERα by E2 or another agonist 
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suppresses transcription of NF-κB in astrocytes and TNF-α-mediated production of pro-
inflammatory CCL2 (Giraud et al., 2010) and to modulate infiltration of peripheral 
lymphocytes into the CNS, whereas ERβ did not show any effect (Spence and Voskuhl, 
2012). In addition, treatment with ERα ligand reduced spinal cord inflammation, 
whereas ERβ ligand treatment only showed protective effects in the long term, but no 
reduction in inflammation (Tiwari-Woodruff and Voskuhl, 2009). These observations 
help explain the relative abundance of inflammatory cells in the parenchyma of the 
spinal cord sections for E3-treated mice versus E2-treated mice in this project, as well as 
the decreased demyelination observed on the Weil’s stained sections. One final 
observation is that E2 increases the ability of astrocytes to resorb excess glutamate, thus 
preventing neuronal loss due to excitotoxicity and explaining the relative effectiveness 
of E2 versus E3 therapeutic effects on treated mice (Spence and Voskuhl, 2012).  
The role of E2 and astrocytes is more complex. Astrocytes are essential 
components of the blood-brain barrier (BBB), and they are important in cell-to-cell 
communication, not only in the CNS, but also with inflammatory cells (Kipp and Beyer, 
2009). E2 has been shown to prevent astrocytes from expressing MHC-II and to enhance 
the induction of T-cell apoptosis, via astrocytes by reduction of H3-thymidine 
incorporation by the T-cells (Kipp and Beyer, 2009). Expression of ERα is necessary in 
astrocytes to prevent axonal loss, gliosis, and diminish or prevent lymphocyte and 
monocyte infiltration into the CNS (Spence et al., 2011). Estradiol is known to have 
positive effects in brain circulation and in young animal models, and reduce stroke 
severity (Cipolla et al., 2009; Selvamani and Sohrabji, 2010). The reduction in stroke 
severity is due to E2’s influence on the BBB, both endothelial cells and astrocytes. 
During stroke, edema causes damage to the parenchyma. Cipolla et al. found that 
ovariectomy in rats increases BBB permeability, but that treatment with E2/E3 
combination therapy restores the integrity of the barrier almost to control level (Cipolla 
et al., 2009) The levels of E2 found in this study are almost at the levels found at estrous 
in the rat ovarian cycle (Shaikh, 1971), making them a comparable measure to the dose 
of E2 given in this study. A similar mechanism may also be taking place in our study: 
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with the maintenance of BBB integrity, less lymphocytes and macrophages would be 
able to migrate into the parenchyma, thus reducing inflammation. The Cipolla study did 
not clarify whether E2 or E3 had a more significant effect on BBB permeability.  
The Theiler’s virus model is effective in showing pathological signs consistent 
with human MS. This model is unique in its biphasic disease onset. Strains such as the 
Daniel’s (DA) and BeAn strain set up an acute gray matter inflammation. Studies using 
Severe Combined Immunodeficient (SCID) mice, showed that the virus could infect 
neurons and glia early on (6h to 7d pi) in both SCID and immunocompetent mice 
establishing infection in the corpus callosum and in hippocampal pyramidal neurons 
(Njenga et al., 1997) leading to the development of pathological polioencephalomyelitis, 
though most mice remain asymptomatic (Sato et al., 2011). In addition, SCID mice had 
virus in neuronal cell bodies in the spinal cord after 7d pi compared to 
immunocompetent mice. This indicated that virus was cleared before 7d pi in 
immunocompetent mice. This study revealed that both cellular and humoral immune 
responses are clearing the virus from gray matter, with the humoral branch being less 
efficient and also that both CD4+ and CD8+ cells have similar functions in gray matter 
viral clearance (Njenga et al., 1997).   
It is not entirely clear why the virus cannot be fully cleared from white matter. It 
has been shown that it can persist in, macrophages, oligodendrocytes, axons, or glia, and 
that the attempt to clear it may be the main cause of the demyelinating chronic pathology 
that follows acute infection (Njenga et al., 1997; Sato et al., 2011). Infection in the 
TMEV model seems to be modulated by TH1 mechanisms and based on our results, 
inflammation in the spinal cord parenchyma corresponds to areas of demyelination. This 
confirms the previous observation. A possible mechanism for the observed pathogenesis 
of TMEV can be elucidated from observations done by previous groups and 
observations from this work. The virus is capable of causing damage to axons, and by 
consequence to myelin and oligodendrocytes or directly infect and kill oligodendrocytes 
(Sato et al., 2011).  
It was determined that the L-protein in Theiler’s virus can inhibit gene 
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transcription, interfere with translation by preventing the export of mRNA from the 
nucleus, and regulate apoptotic signals. Thus the L-protein can cause cell death without 
inflammation (Ghadge et al., 2011). This may explain why the polioencephalomyelitis 
symptoms are limited. E2 treatment has also been show to inhibit Theiler’s virus 
replication (Kipp and Beyer, 2009), which may help explain the reduction in 
pathological findings in this treatment group. 
Theiler’s virus is unique among non-enveloped viruses in that it can exit a cell 
without lysis whereas other non-enveloped viruses need to lyse the cell once their 
replication is complete (Roussarie et al., 2007). This ability may help explain how 
TMEV is able to move from neuron to oligodendrocytes without causing neuronal cell 
death in the majority of cases and setting up a persistent infection in these white matter 
cells. Roussaire et al. propose that TMEV uses conventional cell machinery to migrate 
from axon to myelin and the group mentioned a hypothesis proposed by Gatzinski et al. 
which states axons may use myelin to remove unwanted materials, in this case virions 
(Roussarie et al., 2007). Because of the number of internodes and axons one 
oligodendrocyte can myelinate, its death can cause extensive demyelination. However, 
in the event of axonal damage, demyelination can also occur. Damage in the EAE model 
is accepted to come from “bystander” CD4+-mediated injury to CNS tissue when these 
cells respond to myelin antigen, principally myelin proteolipid protein (PLP) (Sato et al., 
2011) and myelin basic protein (MBP) is also involved in disease pathogenesis in EAE 
(Dal Canto et al., 2000). The PLP epitope used to induce EAE (PLP 139-152) seems to 
be involved in TMEV autoimmunity and as the disease progresses this epitope “spreads” 
to include other regions of the protein and other similar proteins such as Myelin 
Oligodendrocyte Glycoprotein (MOG) (Dal Canto et al., 2000).  
Organotypic spinal cord cultures from SJL/J mice were prepared and treated with 
lymphocytes from TMEV-infected mice. They were then stimulated with MBP or PLP. 
Under MBP stimulation, the axons appeared normal and their numbers did not differ 
from naïve or sham-infected mice cultures; however, under PLP stimulation, the 
majority of the axons were heavily demyelinated (Dal Canto et al., 2000). These results 
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indicate that TMEV mechanisms of action may be different from the EAE model, where 
anti-MBP lymphocytes can cause culture demyelination and transfer disease to naïve 
mice (Dal Canto et al., 2000). EAE could be protected by anti-PLP Ab when whole 
myelin was used to prime the mice while anti-MBP Ab had no effect (Dal Canto et al., 
2000). The TMEV model exhibited similar properties due to the liberation of myelin 
fragments early in the disease (Dal Canto et al., 2000). In addition CD8+ T-cells 
expressing MHC-I infiltrate the CNS to clear the virus, but in doing so cause damage to 
myelin by recognizing self-epitopes (Sato et al., 2011; Tsunoda et al., 2005). 
Experimentally, self-recognizing CD8+ T-cells from MS patients can elicit an immune 
response against CNS tissue in naïve mice, demonstrating the ability of this cell subtype 
to cause CNS pathology (Tsunoda et al., 2005). CD8+ T-cells are the most likely 
candidates for causing axonal damage that leads to demyelination. Roos et al. report that 
both CD4+ and CD8+ T-cells can induce demyelination since depletion of either 
population leads to myelin breakdown, and that the DA strain of TMEV can damage 
myelin in both MHC-I and MHC-II-deficient mice (Roos, 2010). However, mice that 
lack either CD8+ cells or MHC-I have less severe disease outcomes, thus the CD8+ 
population may cause more damage to axons, impede repair mechanisms, and lead to 
demyelination (Roos, 2010).  
The CNS is considered to be an immunoprivileged site. In infection, however, 
this is not the case. The cytokine environment created by inflammatory cells determines 
whether or not the brain will have inflammation and demyelination. CD4+ cells respond 
to TMEV infection early on. Of the two subtypes of T-helper (TH) cells, the response 
mounted against TMEV seems to be TH1-mediated, or pro-inflammatory. TH1 cells are 
polarized by interleukin-12 (IL-12), which is a pro-inflammatory cytokine. CD4+-TH1 
cells will secrete cytokines such as interleukin-2 (IL-2), interferon gamma (IFNγ) and 
tumor necrosis factor beta (TNFβ). These cytokines are involved in cell-mediated 
immunity and work to activate macrophages (MΦ) (via IFNγ), recruit lymphpcytes (via 
TNFβ+IFNγ), cause CD8+ cells to differentiate into cytolytic T-cells (TCL) ( via IL-
2+IFNγ), and switch IgG to IgG2a, which binds to FCγ and binds complement to help in 
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opsonization (Abbas et al., 1996). In MS and EAE, a new subset of TH cells has also 
been implicated in inflammation and demyelination. TH17 cells secrete IL-17 and are 
induced by IL-6 and transforming growth factor beta (TGFβ), and maintained by IL-23, 
a cytokine related to IL-12 by its p40 subunit (Aranami and Yamamura, 2008; Fletcher 
et al., 2010); thus, for a long time, the presence of TH17 cells was unnoticed until 2003, 
when Cua et al. discovered this subgroup of cells (Aranami and Yamamura, 2008). IL-
17 attracts neutrophils into the brain, and causes the release of more pro-inflammatory 
cytokines (Fletcher et al., 2010). TH17 CD4+ cells can induce EAE in naïve mice, thus 
they are now associated with the pathogenesis of chronic demyelinating disease of the 
CNS. It is not surprising that this cytokine environment causes damage to CNS tissue as 
observed in the placebo-treated infected mice.  
Estrogens have been shown to induce a switch to a TH2, or anti-inflammatory 
environment. E2 was shown to inhibit TH1 and TH17 cell differentiation in the EAE 
model of MS via interaction with ERα (Lélu et al., 2011), which is of significance to this 
project. Estrogens are known to induce a shift toward TH2-mediated immunity by 
influencing T-cells directly via interaction with ERα (Giraud et al., 2010), especially 
during pregnancy (Nicot, 2009). 
 Theiler’s virus has been shown to increase expression of cyclooxygenase-2 (COX-2) in 
oligodendrocytes and astrocytes. The enzyme cyclooxygenase-2 (COX-2) converts 
arachidonic acid to prostanoids, which are known to mediate responses during 
inflammation. Of notable interest is the pro-inflammatory molecule Prostaglandin E2 
(PGE2), which is known to induce excitotoxic neuronal death by binding to EP1 
receptors. Similar mechanisms are thought to be at play for oligodendrocyte death 
(Carlson et al., 2010). Treatment with E2 has been shown to protect oligodendrocytes 
from glutamate excitotoxic cell death by reducing expression of COX-2, which renders 
them vulnerable to the toxic effects of glutamate (Carlson et al., 2010; Molina-Holgado 
et al., 2002), and increasing astrocyte reuptake of glutamate (Spence and Voskuhl, 
2012). 
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The TH2 cytokine environment is anti-inflammatory and it causes a shift toward 
humoral immunity. TH2 cells produce cytokines that help reduce inflammation such as 
IL-3, 4, 5, 10, and 13. Some of these cells produce TGFβ, but it is produced in other 
tissues (Abbas et al., 1996) and depending on the cytokine milieu, it can induce a shift 
toward TH17 or induced regulatory T-cells (iTReg) (Aranami and Yamamura, 2008). IL-4 
causes a shift in IgG subclass to neutralizing (non-complement binding) IgG1. In B-cells 
it switches to IgE expression, which helps in mast cell-mediated reactions (response to 
allergens). IL-3, 4, and 5 cause activation of eosinophils and increase the production of 
eotaxin to guide them when dealing with helminthes. IL-4 also inhibits IFNγ and 
prevents MΦ activation, IL-10 inhibits MΦ responses, and TGFβ inhibits activation of 
other leukocytes. Thus, TH2-mediated immunity prevents acute and chronic 
inflammation – including the delayed-type hypersensitivity (DTH) reactions brought 
about by TH1 CD4
+ cells and limit their responses (Abbas et al., 1996).  
During classical infection, it is common to initiate TH1-mediated immunity early 
and then switch to TH2 for control and memory functions (Abbas et al., 1996). However, 
during auoimmune chronic inflammation or infection, having TH1 responses may not be 
ideal. The switch from TH1 to TH2-mediated immunity explains the observations made 
in the inflammation and demyelination sections of this project.  
In addition TH2 CD4
+ cells can induce the shift of uncommitted T-cells into 
iTRegs such as T-regulatory-1 (TR1), TR3, and CD8
+TReg via secretion of anti-
inflammatory cytokines TGFβ and IL-10, and retinoic acid (RA) (Fletcher et al., 2010). 
Natural TRegs (nTRegs) are found in the thymus and they express CD25 and Forkhead box 
P3 (FoxP3) transcription factor on their cell surface (CD25+FoxP3+) to elicit regulatory 
functions (Fletcher et al., 2010). It is known that nTRegs regulate tolerance to self and are 
important in autoimmunity. In MS patients, increased TReg activity correlates with 
symptom remission as the cells try to combat increased inflammation from TH1/TH17 
cells, and one can speculate that perhaps the relapsing-remitting onset of MS may be 
related to success of these cells in controlling inflammation, this however is beyond the 
scope of this project. In the TMEV model, specifically in SJL/J mice, TRegs are 
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preferentially activated, and this prevents the virus from being properly cleared from the 
CNS, which brings us closer to understanding the reason behind the chronic 
inflammation caused by the virus, and also to understanding MS pathogenesis (Getts et 
al., 2010).  
In a recent study by Valor et al., MS pregnant and non-pregnant women were 
recruited to measure the effects of E2 on TRegs (Valor et al., 2011). The results of this 
study showed that E2 enhances TReg generation, in accordance to other studies that 
showed the same (Yates et al., 2010), and increases perforin expression (Valor et al., 
2011). Perforin has been postulated as a mechanism of TReg modus operandi, complete 
with degranulation as in the granzyme-perforin pathway found in TCLs. It also found that 
at higher doses, or levels of E2, such as in pregnancy, TReg perforin expression is 
diminished in accordance to the recruitment of TRegs to the fetal-maternal interface 
(Valor et al., 2011). This novel finding helps explain the reduced levels of inflammation 
and demyelination in the E2-treated mice with more accuracy, and aids in the proposal of 
a mechanism of action for estrogens in the TMEV model of MS. 
B-cells and plasma cells in human MS and in TVID have recently received 
considerable attention. CD138+ cells are commonly attributed the title of mature plasma 
cells. In the CNS these antibody-secreting cells (ASCs) are part of a secretion system 
known as intrathecal antibody production (ITAbP) (Pachner et al., 2007). ITAbP ASCs 
are non-existent in normal CNS tissue, but upon infection with TMEV their numbers 
increase within months of infection and they begin secreting IgG2a class anti-TMEV 
antibodies to try to eliminate the virus (Pachner et al., 2007). Mice infected with the 
BeAn strain of TMEV showed that the levels of antibody were high in cerebrospinal 
fluid (CSF), and that the ITAb-producing cells were found around or in close proximity 
to blood vessels (Pachner et al., 2011). However, repeated exposure may result in cross-
reaction with myelin components, namely galactocerebroside (Sato et al., 2011). In this 
pro-inflammatory milieu mediated by TH1 responses, the principal cytokine interferon 
gamma (IFN-γ) helps promote IgG2a secretion by plasma cells (Dal Canto et al., 2000; 
Nicot, 2009; Peterson et al., 1992; Tsunoda et al., 2005). Antibody titers measured by 
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enzyme-linked immunosorbent assay (ELISA) in SJL/J mice infected with TMEV show 
that IgG2a is preferentially expressed between days 29 and 108 pi. The CNS in these 
mice is under TH1-mediated immunity, thus IgG2a production is regulated by IFNγ. In 
TMEV-resistant C57BL/6 mice, the TH2 environment regulates IgG1 production via IL-4 
(Miller et al., 1995; Peterson et al., 1992). In addition, these cells were found to be in 
locations that parelleled demyelinating lesions, predominantly in ventral white matter 
areas of the spinal cord (Pachner et al., 2011). As mentioned before, E2 and E3 are 
known to switch the TH1-mediated immunity to TH2-mediated (Giraud et al., 2010; 
Nicot, 2009). We used a Radio-Immuno Assay (RIA) using protein-A-I125-labeling to 
measure the amount of TMEV (GD-VII) Antibody in mouse sera. We expected to see a 
difference between the estrogen-treated groups and placebo-treated group. We did not 
find significant differences between E2 and E3-treated mice at any dilution; however, 
both groups were significantly different from placebo-treated mice. These results agree 
with the observations made by Peterson et al. as our experiments show that E2 and E3 
both cause a shift to TH2-mediated immunity and IgG1, while placebo-treated mice stay 
on the TH1-mediated milieu and secrete IgG2a (Peterson et al., 1992). 
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5. CONCLUSION AND FUTURE DIRECTIONS 
 
Our study concludes that the use of estrogens as potential therapeutic agents in a 
murine model of multiple sclerosis is plausible in early disease or as a preventive 
treatment (Vegeto et al., 2008). The use of estrogens, in particular 17-β-estradiol 
ameliorated clinical symptoms, reduced signs of inflammation and demyelination, and 
reduced TMEV antibody counts. This effect is supported by observations made by other 
research groups. Treatment with estriol is not helpful in ameliorating symptoms. Though 
it seems to reduce inflammation mildly and diminish TMEV antibody counts, it does not 
seem to help with demyelination. Though these results are in disagreement with other 
experimental models of MS, there may be differences in the pathogenic mechanisms of 
TMEV that can account for our findings. Figure 5.1 presents a proposed mechanism for 
the beneficial effects of estradiol on TMEV. 
Future studies will need to explore the populations of TH-cells present in the 
lesions, explore the cytokine environments present in the different treatment groups and 
confirm the role of TRegs in this model. Studies of the brain in TMEV have not been 
conducted, thus it would be important to look at the brains in the different treatment 
groups and assess inflammation and demyelination to create a neuroanatomical model 
for the pathogenesis of Theiler’s Murine Encephalomyelitis Virus.  In addition further 
analysis of cytokine profiles in the experimental groups may provide potential 
mechanisms of action of estrogens in modulating the immune response and protecting 
inflammatory demyelination. Studies using hormones such as progesterone for the 
treatment of TVID may also be in order. Finally, to assess whether hormone treatments 
may be effective in males, studies with male mice should be carried out.
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Figure 5.1 Proposed mechanism of action of estradiol in TVID. 
We propose that estrogens, in particular 17-β-estradiol (E2), reduce inflammation and demyelination via interaction with estrogen 
receptors (ERs) in cells of the CNS. The result is a decrease in clinical scores and severity of disease. 
A) E2 induces a switch from a TH1 (pro-inflammatory) to a TH2 (anti-inflammatory) cytokine environment. Interleukin (IL)-4, IL-5, IL-
10, IL-13, and TGFβ are cytokines produced in this environment and they inhibit macrophage activity and modulate T-cell responses 
B) E2 prevents the pro-inflammatory p65 transcription factor of the (NF-κB family) from entering the nucleus to promote transcription of 
inflammatory genes. 
C) Ε2 restores the impermeability of the blood-brain barrier (BBB) following ovariectomy and prevents leukocyte infiltration into the 
CNS. 
D) E2 can inhibit viral replication of TMEV which prevents direct lysis or infection of other cells. 
E) E2 interacts with ERs in astrocytes inducing the reuptake of glutamate (Glu) reducing its excitotoxic effects. It also reduces the 
expression of COX2 in astrocytes reducing the production of prostanoids 
F) COX2 expression in oligodendrocyte has been associated with cell death. E2 inhibits COX2 production in Oligodendrocytes, 
preventing death and demyelination. 
G) E2 induces a switch in immunoglobulin (Ig) class in both B-cells and plasma cells. IgG1 has been associated with a TH2 response and 
less myelin damage due to antibodies. 
H) E2 induces TReg generation and perforin production, which may the mechanism by which these cells regulate autoimmune responses 
 
 
 
 
 
 
 
 
 
 
 
  
53 
 
IgG B-cell 
CD25+FoxP3+ 
TReg 
CD8+ 
CD4+ 
Astrocyte 
MΦ/Microglia 
Endothelial cells 
Oligodendrocyte 
Neuron 
TMEV 
TH2 environment: 
IL-4 
Il-5 
IL-10 
IL-13 
TGFβ 
A 
B 
C 
D 
E 
F 
G 
Perforins 
H 
E2 
E2 
E2 
  
54 
 
REFERENCES 
 
Abbas, A.K., Murphy, K.M., Sher, A., 1996. Functional diversity of helper T 
lymphocytes. Nature. 383, 787-793. 
Abramsky, O., 1994. Pregnancy and multiple sclerosis. Ann Neurol. 36, S38-41. 
Alonso, A., Jick, S., Olek, M.J., Ascherio, A., Jick, H., Hernan, M.A., 2005. Recent use 
of oral contraceptives and the risk of multiple sclerosis. Arch Neurol. 62, 1362-
1365 
Aranami, T., Yamamura, T., 2008. Th17 Cells and autoimmune encephalomyelitis 
(EAE/MS). Allergology International 57, 115-120. 
Bebo, B.F., Fyfe-Johnson, A., Adlard, K., Beam, A.G., Vandenbark, A.A., Offner, H., 
2001. Low-dose estrogen therapy ameliorates experimental autoimmune 
encephalomyelitis in two different inbred mouse strains. Journal of Immunology 
166, 2080-2089. 
Blakemore, W.F., Welsh, C.J., Tonks, P., Nash, A.A., 1988. Observations on 
demyelinating lesions induced by Theiler's virus in CBA mice. Acta Neuropathol 
76, 581-589. 
Calabrese, M., Filippi, M., Rovaris, M., Mattisi, I., Bernardi, V., Atzori, M., Favaretto, 
A., Barachino, L., Rinaldi, L., Romualdi, C., Perini, P., Gallo, P., 2008. 
Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal 
MRI study. Neuroimage 42, 1324-1328. 
Campbell, T., Meagher, M.W., Sieve, A., Scott, B., Storts, R., Welsh, T.H., Welsh, C.J., 
2001. The effects of restraint stress on the neuropathogenesis of Theiler's virus 
infection: I. Acute disease. Brain, Behavior, and Immunity 15, 235-254. 
Carlson, C.a.R., Stephen C, 2006. Multiple sclerosis. Microsoft® Encarta® 2006 
[DVD], Microsoft Corporation. 
Carlson, N.G., Rojas, M.A., Redd, J.W., Tang, P., Wood, B., Hill, K.E., Rose, J.W., 
2010. Cyclooxgenase-2 expression in oligodendrocytes increases sensitivity to 
excitotoxic death. Journal of Neuroinflammation 7, 25-35. 
Chastain, E.M.L., Duncan, D.A.S., Rodgers, J.M., Miller, S.D., 2011. The role of 
antigen presenting cells in multiple sclerosis. Biochimica et Biophysica Acta 
1812, 265-274. 
  
55 
 
Cipolla, M., Godfrey, J., Wiegman, M., 2009. The effect of ovariectomy and estrogen on 
penetrating brain arterioles and blood-brain barrier permeability. 
Microcirculation 16, 685-693. 
Confavreux, C., Hutchinson, M., Hours, M.M., Cortinovis-Tourniaire, P., Moreau, T., 
1998. Rate of pregnancy-related relapse in multiple sclerosis. New England 
Journal of Medicine 339, 285-291. 
Cottrell, D.A., Kremenchutzky, M., Rice, G.P.A., Koopman, W.J., Hader, W., 
Baskerville, J., Ebers, G.C., 1999. The natural history of multiple sclerosis:a 
geographically based study. Brain 122, 625-639. 
Dal Canto, M.C., Calenoff, M.A., Miller, S.D., Vanderlugt, C.L., 2000. Lymphocytes 
from mice chronically infected with Theiler's murine encephalomyelitis virus 
produce demyelination of organotypic cultures after stimulation with the major 
encephalitogenic epitope of myelin proteolipid protein. Epitope spreading in 
TMEV infection has functional activity. Journal of Neuroimmunology 104, 79-
84. 
Fletcher, J.M., Lalor, S.J., Sweeney, C.M., Tubridy, N., Mills, K.H.G., 2010. T cells in 
multiple sclerosis and experimental autoimmune encephalomyelitis. Clinical and 
Experimental Immunology 162, 1-11. 
Fuller, A.C., Kang, B., Kang, H.K., Yahikozowa, H., Dal Canto, M.C., Kim, B.S., 2005. 
Gender bias in Theiler's virus-induced demyelinating disease correlates with the 
level of antiviral immune responses. Journal of Immunology 175, 3955-3963. 
Garay, L., Deniselle, M.C.G., Lima, A., Roig, P., De Nicola, A.F., 2007. Effects of 
progesterone in the spinal cord of a mouse model of multiple sclerosis. J Steroid 
Biochem Mol Biol 107, 228-237. 
Gasperini, C., Ruggieri, S., Pozzilli, C., 2010. Emerging oral treatments in multiple 
sclerosis - clinical utility of cladribine tablets. Ther Clin Risk Manag 6, 391-399. 
Getts, M.T., Richards, M.H., Miller, S.D., 2010. A critical role for virus-specific CD8+ 
CTLs in protection from Theiler's virus-induced demyelination in disease-
susceptible SJL mice. Virology 402, 102-111. 
Ghadge, G.D., Wollmann, R., Baida, G., Traka, M., Roos, R.P., 2011. The L-coding 
region of the DA strain of Theiler's murine encephalomyelitis virus causes 
dysfunction and death of myelin-synthesizing cells. Journal of Virology 85, 
9377-9384. 
Giraud, S.N., Caron, C.M., Pham-Dinh, D., Kitabgi, P., Nicot, A.B., 2010. Estradiol 
inhibits ongoing autoimmune neuroinflammation and NFκB-dependent CCL2 
  
56 
 
expression in reactive astrocytes. Proceedings of the National Academy of 
Sciences of the United States of America 107, 8416-8421. 
Gold, R., Wolinsky, J.S., 2011. Pathophysiology of multiple sclerosis and the place of 
teriflunomide. Acta Neurologica Scandinavica 124, 75-84. 
Gold, S.M., Voskuhl, R.R., 2009. Estrogen and testosterone therapies in multiple 
sclerosis. In: Verhaagen, J., Hol, E.M., Huitenga, I., Wijnholds, J., Bergen, A.B., 
Boer, G.J., Dick, F.S. (Eds.), Progress in Brain Research, Elsevier, New York, 
pp. 239-251.  
Goodin, D.S., 2009. The causal cascade to multiple sclerosis: A model for MS 
pathogenesis. PLoS One 4, e4565. 
Kappel, C.A., Melvold, R.W., Kim, B.S., 1990. Influence of sex on susceptibility in the 
Theiler's murine encephalomyelitis virus model for multiple sclerosis. Journal of 
Neuroimmunology 29, 15-19. 
Kipp, M., Beyer, C., 2009. Impact of sex steroids on neuroinflammatory processes and 
experimental multiple sclerosis. Frontiers in Neuroendocrinology 30, 188-200. 
Lélu, K., Laffont, S., Delpy, L., Paulet, P.-E., Périnat, T., Tschanz, S.A., Pelletier, L., 
Engelhardt, B., Guéry, J.-C., 2011. Estrogen receptor-α signaling in T-
lymphocytes is required for estradiol-mediated inhibition of Th1 and Th17 cell 
differentiation and protection against experimental autoimmune 
encephalomyelitis. Journal of Immunology 187, 2386-2393. 
Libbey, J., Fujinami, R., 2010. Potential triggers of MS molecular basis of multiple 
sclerosis. In: Martin, R., Lutterotti, A. (Eds.), Results and Problems in Cell 
Differentiation, Springer Berlin, pp. 21-42. 
 
Meagher, M., Johnson, R., Young, E., Vichaya, E., Lunt, S., Hardin, E., Connor, M., 
Welsh, C.J.R., 2007. Interleukin-6 as a mechanism for the adverse effects of 
social stress on acute Theiler's virus infection. Brain, Behavior, and Immunity 
21, 1083-1095. 
Mendez-Fernandez, Y.V., Hansen, M.J., Rodriguez, M., Pease, L.R., 2005. Anatomical 
and cellular requirements for the activation and migration of virus-specific CD8+ 
T-cells to the brain during Theiler's virus infection. Journal of Virology 79, 3063-
3070. 
Miller, S.D., Katz-Levy, Y., Neville, K.L., Vanderlugt, C.L., 2001. Virus-induced 
autoimmunity: Epitope spreading to myelin autoepitopes in Theiler's virus 
infection of the central nervous system. In: Michael J. Buchmeier, I.L.C. (Ed.), 
Advances in Virus Research, Academic Press, New York, pp. 199-217.  
  
57 
 
Miller, S.D., McRae, B.L., Vanderlugt, C.L., Nikcevich, K.M., Pope, J.G., Pope, L., 
Karpus, W.J., 1995. Evolution of the T-cell repertoire during the course of 
experimental immune-mediated demyelinating diseases. Immunol Rev 144, 225-
244. 
Molina-Holgado, E., Arévalo-Martı́n, A., Ortiz, S., Vela, J.M., Guaza, C., 2002. 
Theiler's virus infection induces the expression of cyclooxygenase-2 in murine 
astrocytes: inhibition by the anti-inflammatory cytokines interleukin-4 and 
interleukin-10. Neuroscience Letters 324, 237-241. 
Nicot, A., 2009. Gender and sex hormones in multiple sclerosis pathology and therapy. 
Frontiers in Bioscience 14, 4477–4515.  
Njenga, M.K., Asakura, K., Hunter, S.F., Wettstein, P., Pease, L.R., Rodriguez, M., 
1997. The immune system preferentially clears Theiler's virus from the gray 
matter of the central nervous system. Journal of Virology 71, 8592-8601. 
Oleszak, E.L., Chang, J.R., Friedman, H., Katsetos, C.D., Platsoucas, C.D., 2004. 
Theiler's virus infection: A model for multiple sclerosis. Clinical Microbiology 
Reviews 17, 174-207. 
Olsson, T., Hillert, J., 2008. The genetics of multiple sclerosis and its experimental 
models. Current Opinion in Neurology 21, 255-260. 
Owens, G., Gilden, D., Burgoon, M., Yu, X., Bennett, J., 2011. Viruses and multiple 
sclerosis. The Neuroscientist 17, 659-676. 
Pachner, A.R., Brady, J., Narayan, K., 2007. Antibody-secreting cells in the central 
nervous system in an animal model of MS: Phenotype, association with 
disability, and in vitro production of antibody. Journal of Neuroimmunology 190, 
112-120. 
Pachner, A.R., Li, L., Lagunoff, D., 2011. Plasma cells in the central nervous system in 
the Theiler's virus model of multiple sclerosis. Journal of Neuroimmunology 232, 
35-40. 
Palaszynski, K.M., Liu, H., Loo, K.K., Voskuhl, R.R., 2004. Estriol treatment 
ameliorates disease in males with experimental autoimmune encephalomyelitis: 
implications for multiple sclerosis. Journal of Neuroimmunology 149, 84-89. 
Peterson, J.D., Waltenbaugh, C., Miller, S.D., 1992. IgG subclass responses to Theiler's 
murine encephalomyelitis virus infection and immunization suggest a dominant 
role for Th1 cells in susceptible mouse strains. Immunology 75, 652-658. 
  
58 
 
Rinta, S., Airas, L., Elovaara, I., 2010. Is the modulatory effect of pregnancy in multiple 
sclerosis associated with changes in blood apoptotic molecules? Acta 
Neurologica Scandinavica 122, 168-174. 
Roos, R.P., 2010. Pathogenesis of Theiler's murine encephalomyelitis virus-induced 
disease. Clinical and Experimental Neuroimmunology 1, 70-78. 
Roussarie, J.-P., Ruffié, C., Edgar, J.M., Griffiths, I., Brahic, M., 2007. Axon myelin 
transfer of a non-enveloped virus. PLoS One 2, e1331. 
Sato, F., Tanaka, H., Hasanovic, F., Tsunoda, I., 2011. Theiler's virus infection: 
Pathophysiology of demyelination and neurodegeneration. Pathophysiology 18, 
31-41. 
Selvamani, A., Sohrabji, F., 2010. Reproductive age modulates the impact of focal 
ischemia on the forebrain as well as the effects of estrogen treatment in female 
rats. Neurobiol Aging 31, 1618-1628. 
Shaikh, A.A., 1971. Estrone and estradiol levels in the ovarian venous blood from rats 
during the estrous cycle and pregnancy. Biol Reprod 5, 297-307. 
Sicotte, N.L., Liva, S.M., Klutch, R., Pfeiffer, P., Bouvier, S., Odesa, S., Wu, T.C.J., 
Voskuhl, R.R., 2002. Treatment of multiple sclerosis with the pregnancy 
hormone estriol. Annals of Neurology 52, 421-428. 
Sieve, A.N., Steelman, A.J., Young, C.R., Storts, R., Welsh, T.H., Welsh, C.J., Meagher, 
M.W., 2006. Sex-dependent effects of chronic restraint stress during early 
Theiler's virus infection on the subsequent demyelinating disease in CBA mice. 
Journal of Neuroimmunology 177, 46-62. 
Sieve, A.N., Steelman, A.J., Young, C.R., Storts, R., Welsh, T.H., Welsh, C.J.R., 
Meagher, M.W., 2004. Chronic restraint stress during early Theiler's virus 
infection exacerbates the subsequent demyelinating disease in SJL mice. Journal 
of Neuroimmunology 155, 103-118. 
Smith, R., Studd, J.W., 1992. A pilot study of the effect upon multiple sclerosis of the 
menopause, hormone replacement therapy and the menstrual cycle. Journal of the 
Royal Society of Medicine 85, 612-613. 
Smith-Bouvier, D.L., Divekar, A.A., Sasidhar, M., Du, S., Tiwari-Woodruff, S.K., King, 
J.K., Arnold, A.P., Singh, R.R., Voskuhl, R.R., 2008. A role for sex chromosome 
complement in the female bias in autoimmune disease. Journal of Experimental 
Medicine 2008 205, 1099-1108. Epub 2008 Apr 1028. 
  
59 
 
Soldan, S., Alvarez Retuerto, A., Sicotte, N., Voskuhl, R., 2003. Immune modulation in 
multiple sclerosis patients treated with the pregnancy hormone estriol. Journal of 
Immunology 171, 6267-6274. 
Spence, R.D., Hamby, M.E., Umeda, E., Itoh, N., Du, S., Wisdom, A.J., Cao, Y., 
Bondar, G., Lam, J., Ao, Y., Sandoval, F., Suriany, S., Sofroniew, M.V., 
Voskuhl, R.R., 2011. Neuroprotection mediated through estrogen receptor-α in 
astrocytes. Proceedings of the National Academy of Sciences 108, 8867-8872. 
Spence, R.D., Voskuhl, R.R., 2012. Neuroprotective effects of estrogens and androgens 
in CNS inflammation and neurodegeneration. Frontiers in Neuroendocrinology 
33, 105-115. 
Stadelmann, C., Albert, M., Wegner, C., Brck, W., 2008. Cortical pathology in multiple 
sclerosis. Current Opinion in Neurology 21, 229-234. 
Stuart, M., Bergstrom, L., 2011. Pregnancy and multiple sclerosis. Journal of Midwifery 
& Women's Health 56, 41-47. 
Tiwari-Woodruff, S., Voskuhl, R., 2009. Neuroprotective and anti-inflammatory effects 
of estrogen receptor ligand treatment in mice. Journal of the Neurological 
Sciences 286, 81-85. 
Tsunoda, I., Kuang, L.-Q., Kobayashi Warren, M., Fujinami, R., 2005. Central nervous 
system pathology caused by autoreactive CD8+ T-cell clones following virus 
infection. Journal of Virology 79, 14640-14646. 
Valor, L., Teijeiro, R., Aristimuño, C., Faure, F., Alonso, B., de Andres, C., Tejera, M., 
Lopez-Lazareno, N., Fernandez-Cruz, E., Sanchez-Ramon, S., 2011. Estradiol-
dependent perforin expression by human regulatory T-cells. Eur J Clin Invest 41, 
357-364. 
Vegeto, E., Benedusi, V., Maggi, A., 2008. Estrogen anti-inflammatory activity in brain: 
A therapeutic opportunity for menopause and neurodegenerative diseases. 
Frontiers in Neuroendocrinology 29, 507-519. 
Voskuhl, R., 2003. Hormone-based therapies in MS. The International MS Journal 10, 
60-66. 
Voskuhl, R.R., Palaszynski, K., 2001. Sex hormones in experimental autoimmune 
encephalomyelitis: Implications for multiple sclerosis. The Neuroscientist 7, 258-
270. 
  
60 
 
Wang, C., Dehghani, B., Li, Y., Kaler, L.J., Vandenbark, A.A., Offner, H., 2009. 
Oestrogen modulates experimental autoimmune encephalomyelitis and 
interleukin-17 production via programmed death 1. Immunology 126, 329-335. 
Weil, A., 1928. A rapid method for staining myelin sheaths. Arch Neurol Psychiatry 20, 
392-393. 
Welsh, C.J., Tonks, P., Nash, A.A., Blakemore, W.F., 1987. The effect of L3T4 T-cell 
depletion on the pathogenesis of Theiler's murine encephalomyelitis virus 
infection in CBA mice. The Journal of General Virology 68 ( Pt 6), 1659-1667. 
Whitacre, C.C., 2001. Sex differences in autoimmune disease. Nat Immunol. 2, 777-780. 
Yates, M.A., Li, Y., Chlebeck, P., Proctor, T., Vandenbark, A.A., Offner, H., 2010. 
Progesterone treatment reduces disease severity and increases IL-10 in 
experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 220, 
136-139. 
Young, E.E., Sieve, A.N., Vichaya, E.G., Carcoba, L.M., Young, C.R., Ambrus, A., 
Storts, R., Welsh, C.J.R., Meagher, M.W., 2010. Chronic restraint stress during 
early Theiler's virus infection exacerbates the subsequent demyelinating disease 
in SJL mice: II. CNS disease severity. Journal of Neuroimmunology 220, 79-89. 
 
 
 
 
 
 
 
 
 
 
 
  
61 
 
VITA 
 
Name:  Francisco Pascual Gomez 
 
Address: c/o Dr. Jane Welsh 
  Department of Veterinary Integrative Biosciences,  
  College of Veterinary Medicine and Biomedical Science.  
  Mail Stop 4458 
  College Station, TX 77843-4458 
 
Email Address: FPGomez2515@yahoo.com 
 
Education: B.S. Biomedical Sciences, cum laude, Texas A&M University, 2009 
  M.S. Biomedical Sciences, Texas A&M University, 2012 
Admitted to Texas A&M Health Science Center College of Medicine, 
Class of 2016 
 
Awards:  
− Second place graduate poster presentation winner at the 4th Annual 
Faculty of Neuroscience (FNS) Symposium – April 20, 2012 
− Recipient of the Margaret and Charles Plumb Endowed Scholarship 
(Academic year 2011-2012) 
− Recipient of the Patricia A Ward College of Medicine Scholarship 
(Academic year 2010-2011) 
− College of Veterinary Medicine and Biomedical Science Regents’ 
Graduate Fellowship recipient (Academic year 2009-2010) 
 
